<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Nat Commun</journal-id><journal-id journal-id-type="iso-abbrev">Nat Commun</journal-id><journal-title-group><journal-title>Nature Communications</journal-title></journal-title-group><issn pub-type="epub">2041-1723</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40393984</article-id><article-id pub-id-type="pmc">PMC12092839</article-id>
<article-id pub-id-type="publisher-id">59531</article-id><article-id pub-id-type="doi">10.1038/s41467-025-59531-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>CREBBP inactivation sensitizes B cell acute lymphoblastic leukemia to ferroptotic cell death upon BCL2 inhibition</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Garcia-Gimenez</surname><given-names>Alicia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0009-0001-1909-9499</contrib-id><name><surname>Ditcham</surname><given-names>Jonathan E.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9085-4031</contrib-id><name><surname>Azazi</surname><given-names>Dhoyazan M. A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1390-6592</contrib-id><name><surname>Giotopoulos</surname><given-names>George</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Asby</surname><given-names>Ryan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Meduri</surname><given-names>Eshwar</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bagri</surname><given-names>Jaana</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sakakini</surname><given-names>Nathalie</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lopez</surname><given-names>Cecile K.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4106-2166</contrib-id><name><surname>Narayan</surname><given-names>Nisha</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Beinortas</surname><given-names>Tumas</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Agrawal-Singh</surname><given-names>Shuchi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Fung</surname><given-names>Kent</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>O&#x02019;Connor</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6835-3791</contrib-id><name><surname>Mansour</surname><given-names>Marc R.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Alabed</surname><given-names>Husam B. R.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0038-9709</contrib-id><name><surname>Jenkins</surname><given-names>Benjamin</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9998-051X</contrib-id><name><surname>Koulman</surname><given-names>Albert</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1115-9618</contrib-id><name><surname>Murphy</surname><given-names>Michael P.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8418-5783</contrib-id><name><surname>Horton</surname><given-names>Sarah J.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0312-161X</contrib-id><name><surname>Huntly</surname><given-names>Brian J. P.</given-names></name><address><email>bjph2@cam.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4343-4784</contrib-id><name><surname>Richardson</surname><given-names>Simon E.</given-names></name><address><email>ser32@cam.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05nz0zp31</institution-id><institution-id institution-id-type="GRID">grid.449973.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0612 0791</institution-id><institution>Department of Haematology, </institution><institution>Cambridge Stem Cell Institute, </institution></institution-wrap>Cambridge, UK </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05nz0zp31</institution-id><institution-id institution-id-type="GRID">grid.449973.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0612 0791</institution-id><institution>Cambridge Stem Cell Institute, </institution></institution-wrap>Cambridge, UK </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04v54gj93</institution-id><institution-id institution-id-type="GRID">grid.24029.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0383 8386</institution-id><institution>Cambridge University Hospitals, </institution></institution-wrap>Cambridge, UK </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/041kmwe10</institution-id><institution-id institution-id-type="GRID">grid.7445.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2113 8111</institution-id><institution>Centre for Haematology, Department of Immunology and Inflammation, </institution><institution>Imperial College London, </institution></institution-wrap>London, UK </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jx3x895</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2190 1201</institution-id><institution>University College London Cancer Institute, </institution><institution>UCL, </institution></institution-wrap>London, UK </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jx3x895</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution-id institution-id-type="ISNI">0000000121901201</institution-id><institution>UCL Great Ormond Street Institute of Child Health, </institution></institution-wrap>London, UK </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/013meh722</institution-id><institution-id institution-id-type="GRID">grid.5335.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2188 5934</institution-id><institution>Institute of Metabolic Science, </institution><institution>University of Cambridge, </institution></institution-wrap>Cambridge, UK </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00x27da85</institution-id><institution-id institution-id-type="GRID">grid.9027.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 3630</institution-id><institution>Department of Chemistry, Biology and Biotechnology, </institution><institution>University of Perugia, </institution></institution-wrap>06100 Perugia, Italy </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/013meh722</institution-id><institution-id institution-id-type="GRID">grid.5335.0</institution-id><institution-id institution-id-type="ISNI">0000000121885934</institution-id><institution>MRC Mitochondrial Biology Unit, Keith Peters Building, </institution><institution>University of Cambridge, </institution></institution-wrap>Cambridge, UK </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>4274</elocation-id><history><date date-type="received"><day>3</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>24</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">B-cell acute lymphoblastic leukemia (B-ALL) is a leading cause of death in childhood and outcomes in adults remain dismal. There is therefore an urgent clinical need for therapies that target the highest risk cases. Mutations in the histone acetyltransferase <italic>CREBBP</italic> confer high-risk and increased chemoresistance in ALL. Performing a targeted drug-screen in isogenic human cell lines, we identify a number of small molecules that specifically target <italic>CREBBP</italic>-mutated B-ALL, the most potent being the BCL2-inhibitor Venetoclax. Of note, this acts through a non-canonical mechanism resulting in ferroptotic rather than apoptotic cell death. <italic>CREBBP</italic>-mutated cell lines show differences in cell-cycle, metabolism, lipid composition and response to oxidative stress, predisposing them to ferroptosis, which are further dysregulated upon acquisition of Venetoclax resistance. Lastly, small-molecule inhibition of CREBBP pharmacocopies <italic>CREBBP</italic>-mutation, sensitizing B-ALL cells, regardless of genotype, to Venetoclax-induced ferroptosis in-vitro and in-vivo, providing a promising drug combination for broader clinical translation in B-ALL.</p></abstract><abstract id="Abs2" abstract-type="web-summary"><p id="Par2">CREBBP mutations in B-cell acute lymphoblastic leukemia (B-ALL) are linked to poor prognosis and chemoresistance. Here, the authors show that genetic or pharmacological inactivation of CREBBP sensitizes B-ALL cells to the BCL2 inhibitor Venetoclax, inducing ferroptotic cell death and extending survival in B-ALL preclinical mouse models.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Acute lymphocytic leukaemia</kwd><kwd>Cell death</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK (CRUK)</institution></institution-wrap></funding-source><award-id>C67279/A27957</award-id><principal-award-recipient><name><surname>Richardson</surname><given-names>Simon E.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par3">B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive hematological malignancy of B-lineage progenitors and is the commonest cancer in children<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Whilst the majority of children can be cured with multi-agent chemotherapy, patients with high-risk genetic subtypes, certain age groups and those who relapse remain a clinical challenge, such that B-ALL remains a leading cause of death in childhood. Furthermore, outcomes of adults with B-ALL remain dismal, even when fit enough to be treated intensively. There is therefore an urgent need to better understand drivers of high-risk B-ALL and to develop novel therapeutic approaches targeting these challenging patient cohorts.</p><p id="Par4">Mutations in <italic>CREBBP</italic> (CREB-binding protein) are found in multiple hematological and solid malignancies, notably B-cell lymphomas<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref></sup>. Loss-of-function (LOF) mutations affecting <italic>CREBBP</italic> are also recurrent second-hit mutations across multiple genetic subtypes of B-ALL and are associated with adverse features, including high-risk genetic subtypes and persistent measurable residual disease (MRD)<sup><xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref></sup>. In addition, they have been mechanistically associated with chemoresistance and, in keeping with this, are enriched at relapse<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref></sup>. <italic>CREBBP</italic> mutations have also been described as an adverse prognostic factor in ALL, acute myeloid leukemia (AML) and follicular lymphoma<sup><xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref></sup>. CREBBP is a large protein with histone acetyltransferase (HAT) enzymatic activity alongside protein scaffolding function mediated through multiple protein-protein interaction domains, including a bromodomain responsible for binding acetylated lysine residues. Alongside its paralogue EP300, CREBBP is considered to primarily function as a transcriptional co-activator, responsible for acetylating histone residues at gene enhancers and promoters. <italic>CREBBP</italic> LOF mutations can include complete loss of the protein or recurrent point mutations affecting the HAT domain, which appear to exert a stronger phenotype<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. During B-ALL evolution, <italic>CREBBP</italic> mutations frequently become bi-allelic and commonly co-associate with activating RAS pathway mutations, suggesting strong oncogenic co-operativity<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR17">17</xref></sup>.</p><p id="Par5">Targeting cells harboring LOF mutations in tumor suppressor genes (TSG) principally relies on perturbing synthetic lethal dependencies acquired upon loss of TSG activity, commonly via inhibition of redundant pathways or protein paralogues. In the context of <italic>CREBBP</italic>, this has been demonstrated in models of B-cell lymphoma through inhibition of residual EP300 function using small molecule HAT or bromodomain inhibitors<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. Global analyses of genetic co-dependencies have also implicated a dependency of <italic>CREBBP</italic>-mutated tumors on <italic>EXOC5</italic> function<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>, whilst a number of mechanistic studies have identified potentially targetable roles for CREBBP in modulating key cellular processes including DNA damage response, signaling, apoptosis and metabolism<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>.</p><p id="Par6">In this study we sought to develop treatment options targeting <italic>CREBBP</italic>-mutated high-risk B-ALL. We generated isogenic human B-ALL cell lines and undertook a synthetic lethal drug screen focusing on clinically-actionable agents targeting pathways mechanistically associated with CREBBP function. CREBBP LOF resulted in cell cycle and metabolic dysregulation, with prominent changes in lipid metabolism and marked sensitivity to ferroptotic cell death upon small molecule inhibition of the anti-apoptotic regulator BCL2. Inhibition of CREBBP function with small molecule inhibitors could phenocopy this synthetic lethal effect, sensitizing diverse subtypes of B-ALL to BCL2 inhibitors in-vitro and producing a significant survival advantage in-vivo, thus providing a potentially efficacious drug combination across a wider number of B-ALL genotypes.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title><italic>CREBBP</italic>-mutated B-ALL cell lines show increased sensitivity to Venetoclax</title><p id="Par7">To identify candidate therapeutics that specifically target <italic>CREBBP</italic>-mutated high-risk B-ALL, we undertook a synthetic-lethal drug screen. The <italic>CREBBP</italic> wild-type (WT) B-ALL cell line 697 (derived from a patient with high-risk relapsed <italic>E2A::PBX1</italic> B-ALL)<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> was genome-engineered by CRISPR-Cas9 homologous recombination to introduce a recurrent hotspot mutation at arginine 1446 (<italic>CREBBP</italic><sup><italic>R1446C</italic></sup>), which is implicated to exert a dominant-negative effect on CREBBP acetyltransferase activity<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. Several clones were generated, including a homozygous <italic>CREBBP</italic><sup><italic>R1446C</italic></sup> knock-in mutant clone (hereafter, 697<sup><italic>KI</italic></sup>) and a mutant clone containing two frameshift mutations resulting in a complete knockout of CREBBP protein (hereafter, 697<sup><italic>KO</italic></sup>) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1a</xref>). For use in validation studies, the <italic>ETV6::RUNX1</italic>-driven cell line REH (containing three WT copies of <italic>CREBBP</italic>) was also edited, resulting in two compound-heterozygous mutated clones, each including a single allele of the <italic>CREBBP</italic><sup><italic>R1446C</italic></sup> HAT mutation, alongside presumed deleterious mutations of the other two alleles (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1a</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><title>CREBBP-mutated B-ALL cell lines show increased sensitivity to Venetoclax.</title><p><bold>a</bold> Schematic of genome editing strategy used to engineer 697<sup><italic>WT</italic></sup> (black) into isogenic <italic>CREBBP</italic> 697<sup><italic>KI</italic></sup> (blue) and 697<sup><italic>KO</italic></sup> (yellow) clones. Created in BioRender. Huntly, B. (2025) <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/s71p510">https://BioRender.com/s71p510</ext-link>. <bold>b</bold> Cell-based drug screening was performed using a panel of 32 small molecule compounds predicted to have differential sensitivity between <italic>CREBBP</italic> WT and mutant lines. 72&#x02009;h viability was measured by MTS assays using a wide concentration range between 3pM and 30&#x02009;&#x000b5;M in <italic>n</italic>&#x02009;=&#x02009;3 technical replicates and repeated using narrower concentration ranges to define IC<sub>50</sub> where appropriate. Results are presented as an IC<sub>50</sub> ratio of 697<sup><italic>KI</italic></sup> (blue) and 697<sup><italic>KO</italic></sup> (yellow) clones compared to WT. <bold>c</bold> Dose response curves of two CREBBP/EP300 inhibitors Inobrodib (left) and A485 (right) showing enhanced sensitivity of 697<sup><italic>KI</italic></sup> (blue) compared to 697<sup><italic>WT</italic></sup> (black) in 72&#x02009;h MTS viability assay. <italic>n</italic>&#x02009;=&#x02009;3 technical replicates, mean&#x02009;&#x000b1;&#x02009;SD. <bold>d</bold> Dose response curve of 697<sup><italic>WT</italic></sup> (black) and 697<sup><italic>KI</italic></sup> (blue) lines to Venetoclax in 72&#x02009;h MTS viability assay. <italic>n</italic>&#x02009;=&#x02009;3 technical replicates, mean&#x02009;&#x000b1;&#x02009;SD. <bold>e</bold> Growth curve of 697<sup><italic>WT</italic></sup> (black) and 697<sup><italic>KI</italic></sup> (blue) grown in the presence of either DMSO vehicle (dotted lines) or 20&#x02009;nM Venetoclax (solid lines). <italic>n</italic>&#x02009;=&#x02009;3 independent replicates, mean&#x02009;&#x000b1;&#x02009;SD. <bold>f</bold> Mitochondrial depolarization as assessed by staining for JC1 by flow cytometry (488&#x02009;nm 530/30) in response to DMSO vehicle, or Venetoclax at 20 or 2000nM in 697<sup><italic>WT</italic></sup> (black) and 697<sup><italic>KI</italic></sup> (blue) cell lines. <bold>g</bold> Representative flow cytometry plots of externalization of Annexin-V (reported by APC) in response to 24&#x02009;h exposure to DMSO vehicle (left) or Venetoclax 20&#x02009;nM (right) in 697<sup><italic>WT</italic></sup> (top) and 697<sup><italic>KI</italic></sup> (bottom) cell lines. Viability is assessed by 7AAD exclusion. <bold>h</bold> Proportion of viable 7AAD<sup>-ve</sup>Annexin-V<sup>+ve</sup> early apoptotic cells. <italic>n</italic>&#x02009;=&#x02009;3 independent replicates. Mean&#x02009;&#x000b1;&#x02009;SD, 2-way ANOVA <sup>****</sup>, <italic>P</italic>&#x02009;=&#x02009;0.000009. Source data are provided as a Source Data file.</p></caption><graphic xlink:href="41467_2025_59531_Fig1_HTML" id="d33e705"/></fig></p><p id="Par8">We subjected the 697 isogenic cell lines to a targeted drug screen, using a wide range of concentrations, focussed on clinically-actionable drugs in classes implicated or hypothesized to show differential sensitivity in published models of B-cell lymphoma and other <italic>CREBBP</italic>-mutated malignancies (Supplementary Data Table&#x000a0;<xref rid="MOESM3" ref-type="media">1</xref>)<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup>. <italic>CREBBP</italic>-mutated 697 cells were not differentially sensitive to traditional cytotoxic chemotherapy, and paradoxically showed a degree of sensitization to the glucocorticoid Dexamethasone, used in current ALL induction regimens (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref> and Supplementary Data Table&#x000a0;<xref rid="MOESM3" ref-type="media">1</xref> and Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>)<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>. As anticipated, and validating our screen design, inhibitors of CREBBP and its paralogue EP300 (the CREBBP/EP300-specific bromodomain inhibitor Inobrodib and the CREBBP/EP300 acetylase inhibitor A485) exhibited synthetic lethality, consistent with previous reports in B-cell lymphoma (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b, c</xref> and Supplementary Data Table&#x000a0;<xref rid="MOESM3" ref-type="media">1</xref> and Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>)<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>.</p><p id="Par9">Unexpectedly, the most potent hit identified from the screen was the clinical-grade BCL2 inhibitor Venetoclax, which showed a 2-log<sub>10</sub>-fold reduction in IC<sub>50</sub>, in both 697<sup><italic>KI</italic></sup> and 697<sup><italic>KO</italic></sup> clones (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b, d</xref> and Supplementary Data Table&#x000a0;<xref rid="MOESM3" ref-type="media">1</xref> and Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1d</xref>). These findings were validated in isogenic REH lines, with a 1-log<sub>10</sub>-fold reduction in IC<sub>50</sub> in both mutant clones (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1e</xref>). We confirmed this sensitization to Venetoclax in in-vitro proliferation assays by direct cell counting (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1e</xref>). Upon low-dose Venetoclax exposure, <italic>CREBBP</italic>-mutated 697 cells showed enhanced evidence of markers of programmed cell death, including mitochondrial depolarization, externalization of Annexin-V and induction of cleaved PARP and caspase-3 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1f&#x02013;h</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1f</xref>), consistent with the known mechanism-of-action of Venetoclax in inducing apoptotic programmed cell death.</p><p id="Par10">Overall, this focussed drug screen demonstrates that <italic>CREBBP</italic>-mutated B-ALL is: (i) not uniformly chemo-resistant, and (ii) identifies a number of clinically-actionable agents for use in <italic>CREBBP</italic>-mutated high-risk B-ALL, including Dexamethasone, EP300 inhibitors and a potent sensitization to the BCL2 inhibitor Venetoclax.</p></sec><sec id="Sec4"><title>Venetoclax exerts its effect on <italic>CREBBP</italic>-mutated B-ALL cell lines by on-target inhibition of BCL2</title><p id="Par11">We sought to explore the mechanism-of-action of Venetoclax. Venetoclax was developed to induce apoptosis through inhibition of BCL2 binding to the pro-cell death proteins BAK and BAX. However, recently, it has been shown to have alternative mechanisms-of-action, in particular on metabolism and self-renewal, including potential BCL2-independent effects<sup><xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref></sup>. To test whether the mechanism-of-action of Venetoclax in <italic>CREBBP</italic>-mutated B-ALL was through on-target BCL2 inhibition, we employed a doxycycline-inducible shRNA knock-down system, where shRNA expression was directly linked to a fluorescent reporter (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">2a&#x02013;d</xref>)<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>.</p><p id="Par12">Co-culture of 697<sup><italic>WT</italic></sup> or 697<sup><italic>KI</italic></sup> cells expressing one of two unique <italic>BCL2</italic>-targeting shRNAs (reported by mCherry) competed against cells expressing an shRNA targeting the negative-control <italic>renilla</italic> gene (reported by green fluorescent protein (GFP)) showed that 697<sup><italic>KI</italic></sup> cells exhibited a marked competitive disadvantage upon <italic>BCL2</italic>-knockdown, when compared to 697<sup><italic>WT</italic></sup> (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a, b</xref>). This was associated with significant externalization of Annexin-V, consistent with the induction of programmed cell death (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2c, d</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><title>Venetoclax exerts its effect on <italic>CREBBP</italic>-mutated B-ALL cell lines by on-target inhibition of BCL2.</title><p><bold>a</bold> Schematic of doxycycline-inducible shRNA KD system competitive co-culture assay. 697<sup><italic>WT</italic></sup> and 697<sup><italic>KI</italic></sup> cells were stably transfected with two separate doxycycline-inducible shRNAs targeting <italic>BCL2</italic>, reported by mCherry, or a control shRNA targeting <italic>Renilla</italic>, reported by GFP. <italic>BCL2</italic> and <italic>Renilla</italic> shRNA-expressing cells were mixed in equal numbers, doxycycline added to the media (500&#x02009;ng/ml) to induce shRNA expression and the proportion of cells surviving <italic>BCL2/Renilla</italic>-KD analysed by daily flow cytometry. Created in BioRender. Huntly, B. (2025) <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/w63h764">https://BioRender.com/w63h764</ext-link>. <bold>b</bold>
<italic>BCL2</italic> shRNA KD competitive proliferation assay for two different <italic>BCL2</italic>-targeting shRNAs are presented, showing the ratio of <italic>BCL2</italic>-targeting shRNA (mCherry) vs. <italic>Renilla</italic> control (GFP), in 697<sup><italic>KI</italic></sup> normalized to 697<sup><italic>WT</italic></sup> as a percentage. <italic>n</italic>&#x02009;=&#x02009;3 independent replicates, mean&#x02009;&#x000b1;&#x02009;SD. <bold>c</bold> Representative flow cytometry plots of externalization of Annexin-V (APC) in 697<sup><italic>WT</italic></sup> (top) and 697<sup><italic>KI</italic></sup> (bottom) cell lines in response to doxycycline-induced shRNAs targeting <italic>Renilla</italic> (left), or two different <italic>BCL2-</italic>targeting shRNAs (middle and right). Day 6 post induction. Viability is assessed by 7AAD exclusion. <bold>d</bold> Proportion of viable 7AAD<sup>-ve</sup>Annexin-V<sup>+ve</sup> early apoptotic cells normalized to doxycycline-induced <italic>Renilla</italic> control. <italic>n</italic>&#x02009;=&#x02009;3 independent replicates analysed 6 days after induction, mean&#x02009;&#x000b1;&#x02009;SD, 2-way ANOVA <sup>****</sup>, shRNA1 <italic>P</italic>&#x02009;=&#x02009;0.0000003 and shRNA2 <italic>P</italic>&#x02009;=&#x02009;0.00002. <bold>e</bold> Dose response curve of 697<sup><italic>WT</italic></sup> (black) and 697<sup><italic>KI</italic></sup> (blue) to Navitoclax in 72&#x02009;h MTS viability assays. <italic>n</italic>&#x02009;=&#x02009;3 technical replicates, mean&#x02009;&#x000b1;&#x02009;SD. <bold>f</bold> Dose response curve of 697<sup><italic>WT</italic></sup> (black) and 697<sup><italic>KI</italic></sup> (blue) to A1155463 (BCL<sub>XL</sub> only inhibitor, left) and AZD5991 (MCL1 inhibitor, right) in 72&#x02009;h MTS viability assays. <italic>n</italic>&#x02009;=&#x02009;3 technical replicates, mean&#x02009;&#x000b1;&#x02009;SD. Source data are provided as a Source Data file.</p></caption><graphic xlink:href="41467_2025_59531_Fig2_HTML" id="d33e1026"/></fig></p><p id="Par13">Furthermore, 697<sup><italic>KI</italic></sup> cells also showed differential sensitivity to the structurally-unrelated clinical-grade dual BCL2/BCL<sub>XL</sub> inhibitor Navitoclax (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2e</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">2e, f</xref>). Conversely, specific inhibitors of other antiapoptotic proteins (BCL<sub>XL</sub> and MCL1) showed no specificity for <italic>CREBBP</italic>-mutated cells (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2f</xref>), confirming a BCL2-specific effect. Collectively these studies demonstrate that Venetoclax induces programmed cell death in <italic>CREBBP</italic>-mutated B-ALL by on-target BCL2 inhibition and that the sensitivity of 697<sup><italic>KI</italic></sup> cells is specific to BCL2 and does not occur through other anti-apoptotic proteins.</p></sec><sec id="Sec5"><title><italic>CREBBP</italic>-mutated B-ALL cell lines show significant cell cycle and metabolic dysregulation</title><p id="Par14">To further explore the mechanism of action of Venetoclax in <italic>CREBBP</italic>-mutated 697 cells, we undertook bulk RNA sequencing (RNAseq) of 697<sup><italic>WT</italic></sup> and 697<sup><italic>KI</italic></sup> cells, after 24&#x02009;h exposure to either dimethyl sulfoxide (DMSO) vehicle, or low-dose Venetoclax (20&#x02009;nM&#x02014;the IC<sub>50</sub> of 697<sup><italic>KI</italic></sup> cells). Consistent with the role of <italic>CREBBP</italic> as a transcriptional co-activator, the majority of differentially expressed genes (DEGs) between DMSO-vehicle treated 697<sup><italic>WT</italic></sup> and 697<sup><italic>KI</italic></sup> cells were down-regulated (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3a</xref>). Gene Set Enrichment Analysis (GSEA) also showed marked down-regulation of published <italic>Crebbp</italic> target genes from a mouse lymphoma model (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3b</xref>)<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>.</p><p id="Par15">We explored this further using chromatin immunoprecipitation of H3K27ac marks alongside CUT&#x00026;RUN assessment of CREBBP binding sites. 697<sup><italic>KI</italic></sup> showed a reduction in the total number of both CREBBP-bound loci and H3K27ac modified peaks (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3c</xref>). Furthermore, the normalized read enrichment of CREBBP binding at transcriptional start sites (TSSs) was also consistently reduced in 697<sup><italic>KI</italic></sup> vs. 697<sup><italic>WT</italic></sup>, irrespective of differential gene expression, whereas H3K27ac was predominantly lost at TSSs of genes that were downregulated in 697<sup><italic>KI</italic></sup> (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>). Binding and Expression Target Analysis (BETA) linking differential gene expression to CREBBP-bound enhancers confirmed a significant enrichment for gene downregulation near CREBBP-bound enhancers in 697<sup><italic>KI</italic></sup>, with a corresponding up-regulation of DEGs related to CREBBP-bound enhancers in 697<sup><italic>WT</italic></sup> (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>)<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. Collectively, these findings are consistent with the proposed mechanism of the <italic>CREBBP</italic><sup><italic>R1446C</italic></sup> mutation as detrimental to CREBBP co-activator function<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>.<fig id="Fig3"><label>Fig. 3</label><caption><title><italic>CREBBP</italic>-mutated B-ALL cell lines show significant cell cycle and metabolic dysregulation.</title><p><bold>a</bold> Normalized read enrichments of CREBBP binding (dark) and H3K27ac marks (light) in 697<sup><italic>WT</italic></sup> (black) and 697<sup><italic>KI</italic></sup> (blue) centered on transcriptional start sites (TSSs), separated on up-regulated (left), non-differentially expressed (center) and down-regulated genes (right). <bold>b</bold> BETA analysis of association of CREBBP-bound H3K27-acetylated enhancers with gene targets, showing association for active differential gene expression in 697<sup><italic>WT</italic></sup> (top) and repressive differential gene expression in 697<sup><italic>KI</italic></sup> (bottom). Reported <italic>P</italic> values shown in legend. <italic>P</italic> values comparing the UP/DOWN and non-differentially expressed gene sets calculated using the Kolmogorov-Smirnov test. <bold>c</bold> Summary of most significantly down-regulated (left) and up-regulated (right) KEGG pathways from DEGs of RNAseq analysis comparing DMSO vehicle-treated 697<sup><italic>KI</italic></sup> with 697<sup><italic>WT</italic></sup>. <bold>d</bold> GSEA analysis of ranked genes of RNAseq analysis comparing DMSO vehicle-treated 697<sup><italic>KI</italic></sup> with 697<sup><italic>WT</italic></sup>. NES normalized enrichment score, FDR false discovery rate. <bold>e</bold> Comparison of <italic>BCL2</italic> expression in 697<sup><italic>WT</italic></sup> (black) and 697<sup><italic>KI</italic></sup> (blue) cells by RNAseq. Each dot represents one sample. Bars show mean fragments per kilobase of transcript per million fragments mapped (FPKM) value&#x02009;&#x000b1;&#x02009;SD, <italic>n</italic>&#x02009;=&#x02009;3 independent replicates, significance calculated by two-tailed unpaired <italic>t</italic> test, **<italic>P</italic>&#x02009;=&#x02009;0.0038. <bold>f</bold> Proliferation of untreated 697<sup><italic>WT</italic></sup> (black), 697<sup><italic>KI</italic></sup> (blue) and 697<sup><italic>KO</italic></sup> (yellow) cells measured by direct counting. <italic>n</italic>&#x02009;=&#x02009;3 independent replicates, mean&#x02009;&#x000b1;&#x02009;SD. <bold>g</bold> Analysis of cell cycle stage by FUCCI reporter system. Percentage cells in G1, Early S and G2-S-M phases in 697<sup><italic>WT</italic></sup> (black) and 697<sup><italic>KI</italic></sup> (blue) cells. <italic>n</italic>&#x02009;=&#x02009;3 independent replicates, bar shows mean average&#x02009;&#x000b1;&#x02009;SD; significance calculated by 2-way ANOVA, <sup>****</sup><italic>P</italic>&#x02009;=&#x02009;0.00004, Early S <italic>P</italic>&#x02009;=&#x02009;0.0498; G2-S-M <italic>P</italic>&#x02009;=&#x02009;0.0342. <bold>h</bold> Comparison of <italic>CDKN2A</italic> expression in 697<sup><italic>WT</italic></sup> (black) and 697<sup><italic>KI</italic></sup> (blue) cells by RNAseq. Each dot represents one sample. Bars show mean FPKM value&#x02009;&#x000b1;&#x02009;SD, <italic>n</italic>&#x02009;=&#x02009;3 independent replicates, significance calculated by two-tailed unpaired <italic>t</italic> test, <sup>***</sup><italic>P</italic>&#x02009;=&#x02009;0.0002. <bold>i</bold> Glycolytic rate measured by extracellular acidification rate (ECAR) in 697<sup><italic>WT</italic></sup> (black) and 697<sup><italic>KI</italic></sup> (blue) cells. Summary of maximal ECAR. Each dot represents a single replicate acquired from two separate experiments. Significance calculated by two-tailed unpaired <italic>t</italic> test, <sup>****</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;1&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;15</sup>. <bold>j</bold> Mitochondrial oxygen consumption rate (OCR). Summary of basal OCR (left), maximal OCR (middle) and spare respiratory capacity (SRC) (right). Each dot represents a single replicate acquired from two separate experiments. Significance calculated by two-tailed unpaired <italic>t</italic> test, <sup>*</sup>, <italic>P</italic>&#x02009;=&#x02009;0.0315; <sup>****</sup>, Maximal respiration <italic>P</italic>&#x02009;=&#x02009;6.2&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;12</sup>, SRC <italic>P</italic>&#x02009;=&#x02009;7.3&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;7</sup>. Source data are provided as a Source Data file.</p></caption><graphic xlink:href="41467_2025_59531_Fig3_HTML" id="d33e1359"/></fig></p><p id="Par16">KEGG pathway and GSEA analysis of DEGs showed significant down-regulation of signatures associated with apoptosis, in consonance with our functional experiments above (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1f&#x02013;h</xref> and Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3c, d</xref>). However, gene-specific examination of differential expression of apoptotic regulators by KEGG pathway analysis showed a mixed picture, affecting the expression of both pro- and anti-apoptotic genes, including a small but significant up-regulation of <italic>BCL2</italic> itself (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3e</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3d</xref>).</p><p id="Par17">More broadly, KEGG and GSEA pathway analyses showed a differential down-regulation of cell cycle and signaling pathways in 697<sup><italic>KI</italic></sup> (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3c, d</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3e</xref>). We confirmed a relative reduction in proliferative capacity in both 697<sup><italic>KI</italic></sup> and 697<sup><italic>KO</italic></sup> cells compared to 697<sup><italic>WT</italic></sup> by proliferation assays (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3f</xref>). This was associated with a significantly increased proportion of 697<sup><italic>KI</italic></sup> cells in G1 phase alongside reduced Early S/G2-S-M phases (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3g</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3f</xref>) confirming a significant defect in cell cycle progression. Downregulation of cell cycle-associated transcriptional signatures was associated with a marked up-regulation of the tumor suppressor <italic>CDKN2A</italic> (encoding the negative cell-cycle regulator P16<sup>INK4a-ARF</sup>), which is commonly mutated in B-ALL (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3h</xref>). Consistent with this, we observed limited differences in proliferation in isogenic <italic>CREBBP</italic>-mutated REH cell lines, which carry biallelic loss of <italic>CDKN2A</italic> (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3g</xref>).</p><p id="Par18">The majority of transcriptionally up-regulated KEGG and Gene Ontology (GO) pathways were indicative of metabolic dysfunction, and GSEA showed dysregulation of fatty acid metabolism and hypoxic gene signatures (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3c, d</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3h</xref>). Given the close association of cell cycle and metabolism, and the established role of BCL2 and Venetoclax in disturbing mitochondrial respiration<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>, we analysed baseline metabolic differences between 697<sup><italic>WT</italic></sup> and 697<sup><italic>KI</italic></sup> cells using in-vitro metabolic flux assays. Unexpectedly, and despite lower cell cycle progression, 697<sup><italic>KI</italic></sup> cells consistently showed increased rates of both glycolysis and oxidative phosphorylation (OxPhos), including higher rates of both basal and maximal respiration, and an increase in spare respiratory capacity (SRC) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3i, j</xref>; Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3i, j</xref>).</p><p id="Par19">Collectively our model suggests that loss of CREBBP acetyltransferase function results in significant transcriptional dysregulation, affecting multiple cellular processes including apoptosis, cell cycle and metabolism.</p></sec><sec id="Sec6"><title>Venetoclax induces ferroptotic cell death in <italic>CREBBP</italic>-mutated B-ALL cell lines</title><p id="Par20">To explore the transcriptional impact of low-dose Venetoclax treatment of 697<sup><italic>KI</italic></sup> cells, we employed a four-way interaction model to identify genes specifically dysregulated in 697<sup><italic>KI</italic></sup> cells upon Venetoclax treatment (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">4a</xref>). KEGG pathway analyses of these genes showed further down-regulation of cell cycle-associated genes and enrichment for metabolic pathways and ferroptosis in Venetoclax-treated 697<sup><italic>KI</italic></sup> cells (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>). Furthermore, GSEA showed marked up-regulation of genes associated with multiple metabolic processes, including ROS scavenging, ferroptosis and the unfolded protein response (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4b</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><title>Venetoclax induces ferroptotic cell death in <italic>CREBBP</italic>-mutated B-ALL cell lines.</title><p><bold>a</bold> Summary of most significantly down-regulated (top) and up-regulated (bottom) KEGG pathways from DEGs of RNAseq analysis comparing Venetoclax-treated 697<sup><italic>KI</italic></sup> with 697<sup><italic>WT</italic></sup>. <bold>b</bold> GSEA analysis of ranked genes of RNAseq analysis comparing Venetoclax-treated 697<sup><italic>KI</italic></sup> with 697<sup><italic>WT</italic></sup>. <bold>c</bold> Cellular viability assessed by flow cytometry of 697<sup><italic>WT</italic></sup> (left) and 697<sup><italic>KI</italic></sup> (right) cells treated with increasing doses of Venetoclax at 24&#x02009;h either with exposure to the cell-permeant pan-caspase inhibitor Z-VAD (purple) or DMSO control (black). <italic>n</italic>&#x02009;=&#x02009;3 independent replicates, analysed by 2-way ANOVA, <sup>****</sup>, 697<sup><italic>WT</italic></sup>
<italic>P</italic>&#x02009;=&#x02009;0.000006; 697<sup><italic>KI</italic></sup>
<italic>P</italic>&#x02009;=&#x02009;0.0000008. <bold>d</bold> Cellular viability assessed by flow cytometry of 697<sup><italic>WT</italic></sup> (left) and 697<sup><italic>KI</italic></sup> (right) cells treated with increasing doses of Venetoclax at 24&#x02009;h, either with exposure to the ferroptotic inhibitor Liproxstatin 1 (purple) or DMSO control (black). <italic>n</italic>&#x02009;=&#x02009;3 independent replicates, analysed by 2-way ANOVA; <sup>***</sup><italic>P</italic>&#x02009;=&#x02009;0.0004; <sup>****</sup><italic>P</italic>&#x02009;=&#x02009;0.000004. <bold>e</bold> Lipid peroxidation in Venetoclax-treated 697<sup><italic>WT</italic></sup> (black), 697<sup><italic>KI</italic></sup> (blue) and 697<sup><italic>KO</italic></sup> (yellow) cells assessed by BODIPYC<sub>11</sub> expressed as a ratio of FL1:FL3 (488&#x02009;nm 530/30:610/20) mean fluorescence intensity (MFI) normalized to untreated cells. n&#x02009;=&#x02009;3 independent replicates, each dot represents a single sample, mean&#x02009;&#x000b1;&#x02009;SD, two-way ANOVA, <sup>****</sup>, 697<sup><italic>WT</italic></sup> vs. 697<sup><italic>KI</italic></sup><italic>,P</italic>&#x02009;=&#x02009;0.000003, 697<sup><italic>WT</italic></sup> vs. 697<sup><italic>KO</italic></sup><italic>, P</italic>&#x02009;=&#x02009;4&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;4</sup>; <sup>*</sup><italic>P</italic>&#x02009;=&#x02009;0.0179. Source data are provided as a Source Data file.</p></caption><graphic xlink:href="41467_2025_59531_Fig4_HTML" id="d33e1631"/></fig></p><p id="Par21">Ferroptosis is a distinct form of programmed cell death resulting from iron-catalyzed reactive oxygen species (ROS)-mediated damage to unsaturated fatty acids of membrane phospholipids<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. It commonly co-associates with apoptosis and is associated with expression of cell death markers, including Annexin-V externalization<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. We demonstrated evidence of ferroptosis upon Venetoclax treatment, specifically occurring in 697<sup><italic>KI</italic></sup> cells using in-vitro assays. Exposure to the cell-permeable pan-caspase inhibitor Z-VAD partially rescued viability to high-dose Venetoclax in both 697<sup><italic>WT</italic></sup> and 697<sup><italic>KI</italic></sup> cells, indicating a role for intrinsic, caspase-mediated apoptosis induced by high-dose Venetoclax in both lines (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4c</xref>). Conversely, exposure to Liproxstatin 1, which specifically inhibits ferroptosis-associated lipid peroxidation, showed significant rescue only in 697<sup><italic>KI</italic></sup> cells, consistent with ferroptosis being the predominant mechanism of cell death mediating sensitization to low dose BCL2 inhibition (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4d</xref>). BCL2 inhibition with either Venetoclax or Navitoclax was also associated with ferroptosis in 697<sup><italic>KI/KO</italic></sup> and REH<sup><italic>Mut</italic></sup> cells, as shown by elevated BODIPYC<sub>11</sub> staining, an indicator of lipid peroxidation (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4e</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">4b&#x02013;d</xref>). Metabolically, low dose (20&#x02009;nM) Venetoclax specifically resulted in a reduction in both basal and maximal OxPhos only in 697<sup><italic>KI</italic></sup> cells, with no effect seen in 697<sup><italic>WT</italic></sup>. In contrast, high-dose Venetoclax (2000nM) resulted in a marked reduction in OxPhos in both 697<sup><italic>KI</italic></sup> and 697<sup><italic>WT</italic></sup> cells, consistent with the role of BCL2 in regulating mitochondrial outer membrane permeabilization (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">4e</xref>).</p><p id="Par22">Overall, these findings demonstrate that the major driver underlying the sensitivity of <italic>CREBBP</italic>-mutated 697<sup><italic>KI</italic></sup> cells to BCL2 inhibition at low doses is ferroptotic programmed cell death, associated with underlying metabolic dysregulation.</p></sec><sec id="Sec7"><title>CREBBP-mutation affects the redox balance and lipid content of B-ALL cell lines</title><p id="Par23">To better understand the mechanisms underlying ferroptosis susceptibility, we tested the intrinsic susceptibility of 697<sup><italic>WT</italic></sup> and 697<sup><italic>KI</italic></sup> cells to ferroptosis using direct inducers of Reduction-Oxidation (redox) stress. 697<sup><italic>KI</italic></sup> cells were slightly more susceptible to induction of ferroptosis by Erastin, which induces ferroptosis in RAS-mutated tumors, by both inhibiting system xc<sup>-</sup> (a cystine/glutamate antiporter upstream of glutathione production) and the VDAC family of mitochondrial outer membrane anion channels (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5a</xref>)<sup><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref></sup>. Similarly, inhibition of glutathione phospholipid peroxidase activity using the GPX4 inhibitor, RSL3, induced significantly higher levels of lipid peroxidation in 69<italic>7</italic><sup><italic>KI</italic></sup> cells, further demonstrating their enhanced sensitivity to redox stress (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5b</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><title>CREBBP-mutation affects the redox balance and lipid content of B-ALL cell lines.</title><p><bold>a</bold> Viability of 697<sup><italic>WT</italic></sup> (black) and 697<sup><italic>KI</italic></sup> (blue) cells following 48&#x02009;h exposure to Erastin at 15 or 30&#x02009;&#x000b5;M. Viability assessed by 7AAD exclusion using flow cytometry. <italic>n</italic>&#x02009;=&#x02009;3 independent replicates, mean&#x02009;&#x000b1;&#x02009;SD. Two-way ANOVA; *, <italic>P</italic>&#x02009;=&#x02009;0.014. <bold>b</bold> Lipid peroxidation in RSL3-treated 697<sup><italic>WT</italic></sup> (black) and 697<sup><italic>KI</italic></sup> (blue) cells assessed by BODIPYC<sub>11</sub> expressed as a ratio of FL1:FL3 MFI normalized to untreated cells. Mean&#x02009;&#x000b1;&#x02009;SD <italic>n</italic>&#x02009;=&#x02009;6 each dot represents an individual passage from two independent experiments performed on separate days. Two-way ANOVA, <sup>****</sup><italic>P</italic>&#x02009;=&#x02009;0.0005. <bold>c</bold> Volcano plot of total proteomic analysis showing differential protein abundance in 697<sup><italic>KI</italic></sup> vs. 697<sup><italic>WT</italic></sup> (red=increased expression in 697<sup><italic>KI</italic></sup>). Two-sided limma statistical test. To control for the false discovery rate (FDR), <italic>p</italic> values were adjusted using the Benjamini-Hochberg method for multiple testing correction. <italic>n</italic>&#x02009;=&#x02009;4 independent replicates. <bold>d</bold> Total lipidomic analysis showing the concentration of polyunsaturated structural lipids in 697<sup><italic>WT</italic></sup> (black) vs. 697<sup><italic>KI</italic></sup> (blue) (nmol/million cells). Degree of unsaturation is categorized on the x axis. <italic>n</italic>&#x02009;=&#x02009;4 independent replicates, mean&#x02009;&#x000b1;&#x02009;SEM. * <italic>p</italic> value&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic> value&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic> value&#x02009;&#x0003c;&#x02009;0.001. <bold>e</bold> Total lipidomic analysis showing the concentration of ether-linked lipids in 697<sup><italic>WT</italic></sup> (black) vs. 697<sup><italic>KI</italic></sup> (blue) (nmol/million cells). PE-O Alkyl Ether-Linked Phosphatidyl ethanolamine, PE-P Alkenyl Ether-Linked Phosphatidyl ethanolamine (Plasmalogen), PC-O Alkyl Ether-Linked Phosphatidylcholine, PC-P Alkenyl Ether-Linked Phosphatidylcholine (Plasmalogen). <italic>n</italic>&#x02009;=&#x02009;4 independent replicates, mean&#x02009;&#x000b1;&#x02009;SEM. * <italic>p</italic> value&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic> value&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic> value&#x02009;&#x0003c;&#x02009;0.001. <bold>f</bold> Two-sided Pearson correlation with <italic>p</italic> value adjusted for multiple testing using Bonferroni correction of gene sets for ferroptosis compared to <italic>CREBBP</italic> expression in patients with RNAseq data in the TARGET Phase 2 cohort. Each dot represents an individual patient (<italic>n</italic>&#x02009;=&#x02009;203). <bold>g</bold> Two-sided Pearson correlation with <italic>p</italic> value adjusted for multiple testing using Bonferroni correction of RPKM-normalized gene expression compared to <italic>CREBBP</italic> expression from patients with RNA-seq data in the TARGET Phase 2 cohort (<italic>n</italic>&#x02009;=&#x02009;203). Significantly correlated genes are highlighted in red (<italic>P</italic><sub><italic>adj</italic></sub>&#x02009;&#x0003c;&#x02009;0.05) with significantly correlated genes related to ferroptosis annotated. Source data are provided as a Source Data file.</p></caption><graphic xlink:href="41467_2025_59531_Fig5_HTML" id="d33e1896"/></fig></p><p id="Par24">GPX4 is a key inhibitor of lipid peroxidation and has been identified as a recurrent genetic dependency in CRISPR screening of B-ALL cell lines<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. However, despite the differential sensitivity of 697<sup><italic>KI</italic></sup> cells to the GPX4 inhibitor RSL3, no differences in GPX4 protein abundance were detectable by western blot analysis (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">5a</xref>). To investigate the abundance of ROS scavenging proteins more broadly, we performed total proteomics on 697<sup><italic>WT</italic></sup> and 697<sup><italic>KI</italic></sup> cells. To our surprise, 697<sup><italic>KI</italic></sup> cells were characterized by significant up-regulation of proteins in multiple antioxidant pathways, including GSS, GSTM2, SPR, SOD1, CAT and TXNRD2 (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5c</xref>; Supplementary Data Table&#x000a0;<xref rid="MOESM4" ref-type="media">2</xref>), consistent with a compensatory adaptation to ROS-mediated stress. Concordantly, western blot analysis of 4-hydroxynonenal (4HNE) protein adducts, formed in response to lipid peroxidation, indicated lower baseline signal in 697<sup><italic>KI</italic></sup> cells compared to 697<sup><italic>WT</italic></sup>. However, whereas these adducts reduced in response to low dose Venetoclax in 697<sup><italic>WT</italic></sup>, they actually increased in 697<sup><italic>KI</italic></sup>, consistent with a differential ability between the isogenic cell lines to tolerate ferroptotic stress (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">5b</xref>).</p><p id="Par25">Total proteomics also showed significant dysregulation of genes implicated in ferroptosis sensitivity, including down-regulation of VDAC1 and multiple enzymes involved in the synthesis of ether-linked lipids (AGPS, GNPAT, ACSL4) in the 697<sup><italic>KI</italic></sup> cell line (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5c</xref>; Supplementary Data Table&#x000a0;<xref rid="MOESM4" ref-type="media">2</xref>). To assess potential alterations in lipid composition, we therefore performed comprehensive quantitative lipidomic analysis, using high-resolution mass spectrometry of 697<sup><italic>WT</italic></sup> and 697<sup><italic>KI</italic></sup> cell lines. Whilst the total levels of major structural membrane lipids were similar between the cell lines (Supplementary Data Table&#x000a0;<xref rid="MOESM5" ref-type="media">3</xref>), 697<sup><italic>KI</italic></sup> cells had markedly higher levels of polyunsaturated fatty acids (PUFAs) in their structural lipid species, which are more vulnerable to ROS damage and lipid peroxidation (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5d</xref>; Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">5c</xref>). Furthermore, consistent with the transcriptional down-regulation of <italic>AGPS</italic>, and low protein levels of GNPAT and ACSL4, 697<sup><italic>KI</italic></sup> cells had very low levels of ether-linked lipids: alkyl-acylphospholipids and alkenyl-acylphospholipids (plasmalogens) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5e</xref>). Ether-linked lipids are synthesized in peroxisomes and the endoplasmic reticulum, and play key signaling roles in these compartments, as well as in the regulation of mitochondrial redox control, including the regulation of ROS balance and PUFA storage<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup>, and their concentration is inversely correlated to ferroptosis sensitivity in different models<sup><xref ref-type="bibr" rid="CR35">35</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref></sup>.</p><p id="Par26">Lastly, we sought to cross-correlate the findings from our cell line models with transcriptional analysis from the large Phase 2 TARGET patient cohort<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. Only a small number of patients were identified to carry <italic>CREBBP</italic> mutations, therefore to more holistically link CREBBP-activity to ferroptotic susceptibility, we correlated gene sets involved in ferroptosis with <italic>CREBBP</italic> expression, demonstrating a highly significant negative correlation (<italic>R</italic>&#x02009;=&#x02009;&#x02013;0.42, p&#x02009;=&#x02009;6.6e<sup>&#x02013;10</sup>) (Supplementary Data Table&#x000a0;<xref rid="MOESM6" ref-type="media">4</xref>, Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5f</xref>). Consistent with the total proteomic analysis in Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5c</xref>, low-<italic>CREBBP</italic>-expressing patients demonstrated upregulation of ROS scavenger genes, including <italic>GPX1, TXN2</italic> and <italic>SOD1</italic>, peroxisomal/ether lipid regulators, including <italic>PEX7</italic> and <italic>FAR2</italic>, and relative downregulation of anti-ferroptotic regulators such as <italic>ASCL3</italic> (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5g</xref>).</p><p id="Par27">Overall, these findings demonstrate that <italic>CREBBP</italic>-mutated 697<sup><italic>KI</italic></sup> cells exhibit up-regulation of ROS scavenging pathways, increased polyunsaturation of structural lipids and depletion of ether-linked signaling lipids. The analysis of patient transcriptional data corroborates that low <italic>CREBBP</italic>-expression correlates with these signatures, suggesting this may be conserved in multiple subtypes of B-ALL.</p></sec><sec id="Sec8"><title>Acquisition of Venetoclax resistance results in transcriptional convergence</title><p id="Par28">Treating cancer with single agents almost inevitably results in acquired treatment resistance, which can often be mitigated by combination therapies. Understanding resistance pathways can: (i) provide insight into pharmacological mechanism-of-action; (ii) identify agents effective in relapse and; (iii) identify novel sensitivities to prevent resistance and improve primary treatment efficacy.</p><p id="Par29">Venetoclax-resistant 697<sup><italic>WT</italic>-Res</sup> and 697<sup><italic>KI</italic>-Res</sup> cells were generated in parallel, by escalated exposure to Venetoclax, to generate lines capable of proliferating in 2000nM Venetoclax (the IC<sub>50</sub> dose of 697<sup><italic>WT</italic></sup>) (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">6a</xref>). Resistant cells were transcriptionally compared to sensitive parental lines by bulk RNAseq. Global profiling by principal component analysis showed the major transcriptional variance separating resistant from sensitive lines (PC1; 77% variance) (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6a</xref>). Venetoclax resistance resulted in a high degree of transcriptional concordance between resistant cell lines, with 697<sup><italic>WT</italic>-Res</sup>/697<sup><italic>KI</italic>-Res</sup> cells differing by only 31 (LFC&#x02009;&#x0003e;&#x02009;1) (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">6b</xref>) compared to 559 DEGs between 697<sup><italic>WT</italic></sup>/697<sup><italic>KI</italic></sup>. Notably, the most differentially down-regulated genes in 697<sup><italic>KI</italic>-Res</sup>/697<sup><italic>WT</italic>-Res</sup> were the redox-sensing selenoprotein <italic>SELENON</italic> and the ether-linked lipid biosynthetic enzyme and ferroptosis regulator <italic>AGPS</italic><sup><xref ref-type="bibr" rid="CR39">39</xref></sup>, one of the most transcriptionally down-regulated genes in 697<sup><italic>KI</italic></sup> vs. 697<sup><italic>WT</italic></sup>, and which is derepressed in 697<sup><italic>KI</italic>-Res</sup> (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">6c</xref>). Functionally, 697<sup><italic>KI</italic>-Res</sup> cells also showed complete reversal of their sensitization to lipid peroxidation upon GPX4 inhibition with RSL3 (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6b</xref>).<fig id="Fig6"><label>Fig. 6</label><caption><title>Acquisition of Venetoclax resistance results in transcriptional convergence.</title><p><bold>a</bold> Principal component analysis of global transcriptional profile by RNAseq of 697<sup><italic>WT</italic></sup> (black), 697<sup><italic>KI</italic></sup> (blue), 697<sup><italic>WT</italic>-Res</sup> (gray) and 697<sup><italic>KI</italic>-Res</sup> (pale blue) cells by RNAseq. <italic>n</italic>&#x02009;=&#x02009;3 independent replicates, each dot represents one sample. <bold>b</bold> Lipid peroxidation in RSL3-treated 697<sup><italic>WT</italic></sup> (black plain), 697<sup><italic>KI</italic></sup> (blue plain), 697<sup><italic>WT</italic>-Res</sup> (black hashed) and 697<sup><italic>KI</italic>-Res</sup> (blue hashed) cells assessed by BODIPYC<sub>11</sub> expressed as a ratio of FL1:FL3 MFI normalized to untreated cells and expressed as a percentage of parental 697<sup><italic>WT</italic></sup>. Mean&#x02009;&#x000b1;&#x02009;SD <italic>n</italic>&#x02009;=&#x02009;6 each dot represents an individual passage from two independent experiments performed on separate days. Two-way ANOVA. <bold>c</bold> Comparison of <italic>BCL2</italic> expression levels in 697<sup><italic>WT</italic></sup> (black) and 697<sup><italic>KI</italic></sup> (blue) cells comparing parental and Venetoclax-resistant lines. Each dot represents one sample. Bars show mean FPKM value&#x02009;&#x000b1;&#x02009;SD, <italic>n</italic>&#x02009;=&#x02009;3 independent replicates. Two-way ANOVA, <sup>****</sup>, 697<sup><italic>WT</italic></sup>
<italic>P</italic>&#x02009;=&#x02009;4.8&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;8</sup> and 697<sup><italic>KI</italic></sup>
<italic>P</italic>&#x02009;=&#x02009;4&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;8</sup>. <bold>d</bold> GSEA of ranked RNAseq expression for E2F cell cycle signatures in 697<sup><italic>WT</italic>-Res</sup> vs. 697<sup><italic>WT</italic></sup> (left), 697<sup><italic>KI</italic>-Res</sup> vs. 697<sup><italic>KI</italic></sup> (middle) and 697<sup><italic>KI</italic>-Res</sup> vs. 697<sup><italic>WT</italic>-Res</sup> (right). <bold>e</bold> Comparison of <italic>CDKN1A</italic> (left) and <italic>CDKN2A</italic> (right) expression levels in 697<sup><italic>WT</italic></sup> (black) and 697<sup><italic>KI</italic></sup> (blue) cells comparing parental and Venetoclax-resistant lines. Each dot represents one sample. Bars show mean FPKM value&#x02009;&#x000b1;&#x02009;SD, <italic>n</italic>&#x02009;=&#x02009;3 independent replicates. Two-way ANOVA, <sup>****</sup>, left: 697<sup><italic>WT</italic></sup>
<italic>P</italic>&#x02009;=&#x02009;6&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;8</sup> and 697<sup><italic>KI</italic></sup>
<italic>P</italic>&#x02009;=&#x02009;1.1&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;8</sup>; right: 697<sup><italic>WT</italic></sup>
<italic>P</italic>&#x02009;=&#x02009;0.00006 and 697<sup><italic>KI</italic></sup>
<italic>P</italic>&#x02009;=&#x02009;4.9&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;8</sup>. <bold>f</bold> Summary of basal (left) and maximal (right) mitochondrial OCR in 697<sup><italic>WT</italic></sup> (black) and 697<sup><italic>KI</italic></sup> (blue) cells comparing parental and resistant lines. Each dot represents a single replicate acquired from two separate experiments. One way ANOVA, <sup>****</sup>, left: 697<sup><italic>WT</italic></sup> vs. 697<sup><italic>WT-Res</italic></sup>
<italic>P</italic>&#x02009;=&#x02009;2.1&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;10</sup>, 697<sup><italic>WT-Res</italic></sup> vs. 697<sup><italic>KI-Res</italic></sup>
<italic>P</italic>&#x02009;=&#x02009;1.2&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;9</sup>, 697<sup><italic>KI</italic></sup> vs. 697<sup><italic>KI-Res</italic></sup>
<italic>P</italic>&#x02009;=&#x02009;1.9&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;11</sup>; right: 697<sup><italic>WT</italic></sup> vs. 697<sup><italic>WT-Res</italic></sup>
<italic>P</italic>&#x02009;=&#x02009;2&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;11</sup>, 697<sup><italic>KI</italic></sup> vs. 697<sup><italic>KI-Res</italic></sup>
<italic>P</italic>&#x02009;=&#x02009;2&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;11</sup>. <bold>g</bold> Summary of glycolytic rate (ECAR) in 697<sup><italic>WT</italic></sup> (black) and 697<sup><italic>KI</italic></sup> (blue) cells comparing parental and resistant lines. Each dot represents a single replicate acquired from two separate experiments. One way ANOVA, <sup>****</sup>, 697<sup><italic>WT</italic></sup> vs. 697<sup><italic>WT-Res</italic></sup>
<italic>P</italic>&#x02009;=&#x02009;8.7&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;7</sup>, 697<sup><italic>KI</italic></sup> vs. 697<sup><italic>KI-Res</italic></sup>
<italic>P</italic>&#x02009;&#x0003c;&#x02009;1&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;15</sup>. Source data are provided as a Source Data file.</p></caption><graphic xlink:href="41467_2025_59531_Fig6_HTML" id="d33e2480"/></fig></p><p id="Par30">Both 697<sup><italic>WT</italic>-Res</sup> and 697<sup><italic>KI</italic>-Res</sup> cells significantly up-regulated <italic>BCL2</italic> (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6c</xref>), but showed no consistent changes in <italic>MCL1</italic> or <italic>BCL</italic><sub><italic>XL</italic></sub> (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">6d</xref>). GSEA showed prominent up-regulation of cell cycle signatures in both resistant lines, which was more marked in 697<sup><italic>KI</italic>-Res</sup> cells compared to 697<sup><italic>WT</italic>-Res</sup> (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6d</xref>). This was associated with down-regulation of <italic>CDKN1A</italic> (encoding the cellular senescence regulator P21) in both lines and a specific down-regulation of <italic>CDKN2A</italic> in the 697<sup><italic>KI</italic>-Res</sup> cells<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6e</xref>).</p><p id="Par31">Metabolic signatures were prominently up-regulated in both resistant cells, although distinct changes were seen for OxPhos, hypoxia and RAS pathway signatures (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">6e</xref>). Functional metabolic profiling demonstrated reduced basal and maximal respiration upon resistance in both lines (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6f</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">6f</xref>). Conversely, glycolytic rate increased upon resistance in 697<sup><italic>WT</italic></sup> cells, whereas it was markedly reduced in 697<sup><italic>KI</italic></sup> cells, indicating differential metabolic reprogramming upon Venetoclax resistance (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6g</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">6g</xref>).</p><p id="Par32">Collectively, these findings identify multiple adaptations upon Venetoclax resistance that were shared by 697<sup><italic>WT</italic>-Res</sup> and 697<sup><italic>KI</italic>-Res</sup> cells, including transcriptional up-regulation of <italic>BCL2</italic>, a reduction in the rate of oxidative phosphorylation and transcriptional upregulation of <italic>VDAC1</italic>, alongside the reversal of specific phenotypes acquired upon <italic>CREBBP</italic> loss in 697<sup><italic>KI</italic></sup> cells, including normalization of <italic>CDKN2A</italic> expression<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> and glycolytic rate, and re-expression of the plasmalogen lipid regulator <italic>AGPS</italic>.</p></sec><sec id="Sec9"><title>Acquisition of Venetoclax resistance sensitizes cells to Erastin</title><p id="Par33">KEGG pathway analysis showed significant transcriptional changes in ferroptotic and cellular senescence pathways specifically in 697<sup><italic>KI-</italic>Res</sup> cells, driven by down-regulation of <italic>P16</italic><sup><italic>INK4A-ARF</italic></sup> and up-regulation of multiple <italic>VDAC</italic> genes, notably <italic>VDAC1</italic> (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7a</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">7a, b</xref>). VDAC proteins are macro-molecular anion channels located in the outer mitochondrial membrane that co-ordinate apoptosis, ferroptosis, mitochondrial metabolism and directly interact with BCL2<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. The ferroptosis inducer Erastin works in part by inhibition of VDAC members, including VDAC1<sup><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR42">42</xref></sup>. In contrast to RSL3 (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6b</xref>), we found a marked induction of Erastin sensitivity upon acquisition of Venetoclax resistance in both resistant cell lines (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7b</xref>). Moreover, co-exposure of 697<sup><italic>WT</italic></sup>, 697<sup><italic>WT</italic>-Res</sup> and 697<sup><italic>KI</italic>-Res</sup> cells to increasing doses of Venetoclax and/or Erastin demonstrated pharmacological synergy, indicating a potential route to both overcome and prevent Venetoclax resistance (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7c</xref>).<fig id="Fig7"><label>Fig. 7</label><caption><title>Acquisition of Venetoclax resistance sensitizes cells to Erastin.</title><p><bold>a</bold> Comparison of <italic>VDAC1</italic> expression levels by RNAseq in 697<sup><italic>WT</italic></sup> (black) and 697<sup><italic>KI</italic></sup> (blue) cells comparing parental and Venetoclax-resistant lines. Each dot represents one sample. Bars show mean FPKM value&#x02009;&#x000b1;&#x02009;SD, <italic>n</italic>&#x02009;=&#x02009;3 independent replicates. Two-way ANOVA, <sup>****</sup>, 697<sup><italic>WT</italic></sup>
<italic>P</italic>&#x02009;=&#x02009;4.5&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;10</sup> and 697<sup><italic>KI</italic></sup>
<italic>P</italic>&#x02009;=&#x02009;5&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;11</sup>. <bold>b</bold> Viability of 697<sup><italic>WT</italic></sup> (black), 697<sup><italic>KI</italic></sup> (blue) cells comparing parental (plain) and resistant (hashed) lines following 48&#x02009;h exposure to Erastin at 15 or 30&#x02009;&#x000b5;M. Viability assessed by 7AAD exclusion using flow cytometry. <italic>n</italic>&#x02009;=&#x02009;3 independent replicates, mean&#x02009;&#x000b1;&#x02009;SD. Two-way ANOVA, <sup>****</sup>, 15&#x02009;&#x000b5;M: 697<sup><italic>WT</italic></sup> vs. 697<sup><italic>WT-Res</italic></sup>
<italic>P</italic>&#x02009;=&#x02009;2.3&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;14</sup>, 697<sup><italic>WT-Res</italic></sup> vs. 697<sup><italic>KI-Res</italic></sup>
<italic>P</italic>&#x02009;=&#x02009;7.5&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;6</sup>, 697<sup><italic>KI</italic></sup> vs. 697<sup><italic>KI-Res</italic></sup>
<italic>P</italic>&#x02009;=&#x02009;2.4&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;14</sup>; 30&#x02009;&#x000b5;M: 697<sup><italic>WT</italic></sup> vs. 697<sup><italic>WT-Res</italic></sup>
<italic>P</italic>&#x02009;=&#x02009;2.3&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;14</sup>, 697<sup><italic>WT-Res</italic></sup> vs. 697<sup><italic>KI-Res</italic></sup>
<italic>P</italic>&#x02009;=&#x02009;3.4&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;6</sup>, 697<sup><italic>KI</italic></sup> vs. 697<sup><italic>KI-Res</italic></sup>
<italic>P</italic>&#x02009;=&#x02009;2.3&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;14</sup>. <bold>c</bold> Three-dimensional diffusion plot of ZIP synergy score to combined doses of synchronous Erastin and Venetoclax in 697<sup><italic>WT</italic></sup> (left) (peak ZIP 41.37), 697<sup><italic>WT</italic>-Res</sup> (middle) (peak ZIP 33.34)and 697<sup><italic>KI</italic>-Res</sup> (right) (peak ZIP 22.69). Viability measured by 72&#x02009;h MTS assay. Source data are provided as a Source Data file.</p></caption><graphic xlink:href="41467_2025_59531_Fig7_HTML" id="d33e2831"/></fig></p></sec><sec id="Sec10"><title>Pharmacological inhibition of CREBBP function can sensitize B-ALL cell lines to Venetoclax in-vitro</title><p id="Par34">The majority of B-ALL patients do not have <italic>CREBBP</italic>-mutations. Given the strength of the association with Venetoclax sensitization we hypothesized that pharmacological inhibition of <italic>CREBBP</italic><sup><italic>WT</italic></sup> function could sensitize <italic>CREBBP</italic><sup><italic>WT</italic></sup> B-ALL to BCL2 inhibitors.</p><p id="Par35">We first pre-treated 697<sup><italic>WT</italic></sup> or REH<sup><italic>WT</italic></sup> cells with the preclinical CREBBP/EP300 HAT inhibitor A485 for 3 days, aiming to generate a stable reduction of CREBBP-mediated acetylation. A485 exposure almost perfectly phenocopied the Venetoclax sensitization seen in our isogenic lines (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8a</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">8a</xref>). Furthermore, co-treatment with A485 and Venetoclax showed strong pharmacological synergy (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8b</xref>). Further corroborating our isogenic findings, A485-sensitized Venetoclax cytotoxicity was associated with enhanced lipid peroxidation, consistent with ferroptosis (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8c</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">8b</xref>). Similar results were also seen with the orally-available CREBBP/EP300-specific bromodomain inhibitor Inobrodib, which is currently in clinical trials (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">8c,d</xref>). In both 697<sup><italic>WT</italic></sup> and REH<sup><italic>WT</italic></sup> cells, A485-induced HAT inhibition was associated with increased basal and maximal OxPhos with an increase in SRC, similar to that seen in 697<sup><italic>KI</italic></sup> cells (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8d</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">8e&#x02013;g</xref>). Single-agent A485-treated 697<sup><italic>WT</italic></sup> cells showed no loss of proliferation or evidence of programmed cell death by annexin-V externalization, strongly suggesting that, at these doses, A485 works by sensitizing cells to Venetoclax-induced cytotoxicity (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8e, f</xref>).<fig id="Fig8"><label>Fig. 8</label><caption><title>Pharmacological inhibition of CREBBP function can sensitize B-ALL cell lines to Venetoclax in-vitro<italic>.</italic></title><p><bold>a</bold> Dose response curve of 697<sup><italic>WT</italic></sup> (black) and 697<sup><italic>WT</italic></sup> pre-treated with 3 days of A485 (pale blue) to Venetoclax in 72&#x02009;h MTS viability assays. <italic>n</italic>&#x02009;=&#x02009;3 technical replicates, mean&#x02009;&#x000b1;&#x02009;SD. <bold>b</bold> Three-dimensional diffusion plot of ZIP synergy score to combined doses of synchronous A485 and Venetoclax (peak ZIP 62.24) in 697<sup><italic>WT</italic></sup> cells. Viability measured by 72&#x02009;h MTS assay. <bold>c</bold> Summary BODIPYC<sub>11</sub> staining 697<sup><italic>WT</italic></sup> (black) and 697<sup><italic>WT</italic></sup> treated with A485 (pale blue) cells in response to Venetoclax. FL1:FL3 signal normalized to DMSO vehicle. <italic>n</italic>&#x02009;=&#x02009;3 independent replicates, each dot represents a single sample, mean&#x02009;&#x000b1;&#x02009;SD, two-way ANOVA, <sup>***</sup><italic>P</italic>&#x02009;=&#x02009;0.0006, <sup>****</sup><italic>P</italic>&#x02009;=&#x02009;1.2&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;6</sup>. <bold>d</bold> Summary of basal (left) and maximal (middle) mitochondrial oxygen consumption rate (OCR) and spare respiratory capacity (right) measured using Seahorse (Agilent) Mitostress test in 697<sup><italic>WT</italic></sup> cells treated with A485 (pale blue) or DMSO vehicle (black). Each dot represents a single replicate acquired from two separate experiments. Two-tailed unpaired <italic>t</italic> test <sup>****</sup>, Basal respiration <italic>P</italic>&#x02009;=&#x02009;9.2&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;8</sup>, Maximal respiration <italic>P</italic>&#x02009;=&#x02009;5.5&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;8</sup>, SRC <italic>P</italic>&#x02009;=&#x02009;7.3&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;7</sup>. <bold>e</bold> Growth curve of 697<sup><italic>WT</italic></sup> cells treated with Venetoclax 100&#x02009;nM and/or A485 at two different doses (100&#x02009;nM and 300&#x02009;nM). Mean of duplicate independent replicates presented as log<sub>2</sub> accumulative fold change. <bold>f</bold> Annexin-V (APC) externalization assessed by flow cytometry in 697<sup><italic>WT</italic></sup> cells treated with Venetoclax 100&#x02009;nM and/or A485 at two different doses (100&#x02009;nM and 300&#x02009;nM). Duplicate measurements, each dot represents a single independent replicate, MFI&#x02009;&#x000b1;&#x02009;SD normalized to DMSO control. <bold>g</bold> Dose response curve of NALM6<sup><italic>WT</italic></sup> (solid line) and NALM6<sup><italic>WT</italic></sup> pre-treated with 3 days of A485 (hashed line) to Venetoclax in 72&#x02009;h MTS viability assays. <italic>n</italic>&#x02009;=&#x02009;3 technical replicates, mean&#x02009;&#x000b1;&#x02009;SD. <bold>h</bold> Summary BODIPYC<sub>11</sub> staining NALM6<sup><italic>WT</italic></sup> (red) and NALM6<sup><italic>WT</italic></sup> treated with A485 (brown) cells in response to Venetoclax. FL1:FL3 signal normalized to DMSO vehicle. <italic>n</italic>&#x02009;=&#x02009;3 independent replicates, each dot represents a single sample, mean&#x02009;&#x000b1;&#x02009;SD, two-way ANOVA, <sup>****</sup>1&#x02009;&#x000b5;M&#x02009;<italic>P</italic>&#x02009;=&#x02009;4.9&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;7</sup>, 10&#x02009;&#x000b5;M&#x02009;<italic>P</italic>&#x02009;=&#x02009;5.6&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;8</sup>, 30&#x02009;&#x000b5;M&#x02009;<italic>P</italic>&#x02009;=&#x02009;4&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;11</sup>. <bold>i</bold> Three-dimensional diffusion plot of ZIP synergy score to combined doses of A485 and Venetoclax. Viability measured by 72&#x02009;h MTS assays in Venetoclax-sensitive cell lines: SUPB15 (<italic>BCR::ABL1</italic>) (peak ZIP 13.86), KOPN8 (<italic>MLL::ENL</italic>) (peak ZIP 12.66) and RS4-11 (<italic>MLL::AF4</italic>) (peak ZIP 27.08). Source data are provided as a Source Data file.</p></caption><graphic xlink:href="41467_2025_59531_Fig8_HTML" id="d33e3073"/></fig></p><p id="Par36">We extended these findings to other human B-ALL cell lines, across a range of genotypes. A485 sensitized the highly Venetoclax-resistant, <italic>BAX</italic>-mutated cell line NALM6 to Venetoclax (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8g</xref>). This was associated with increased lipid peroxidation, indicative of ferroptotic death (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8h</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">8h</xref>). Even in Venetoclax-sensitive B-ALL lines driven by high-risk genetic drivers, Venetoclax and A485 showed evidence of further pharmacological synergy (defined as a peak ZIP score &#x02265;10), indicating that this interaction is conserved across diverse genetic subtypes of B-ALL (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8i</xref>).</p><p id="Par37">Collectively, these data pharmacologically validate the findings of BCL2 sensitization identified in our <italic>CREBBP</italic>-mutated cell lines and support a possible drug combination for clinical translation in B-ALL more broadly.</p></sec><sec id="Sec11"><title>Genetic or pharmacological inhibition of CREBBP sensitizes B-ALL to Venetoclax in-vivo</title><p id="Par38">Finally, we sought to test whether Venetoclax could target <italic>CREBBP</italic>-mutated B-ALL in-vivo, where cell extrinsic factors and pharmacodynamic effects can result in reduced efficacy or highlight dose-limiting toxicities.</p><p id="Par39">Luciferase-expressing 697<sup><italic>WT</italic></sup> and 697<sup><italic>KI</italic></sup> cell lines were engrafted into NOD-SCID-Gamma (NSG) mice (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9a,b</xref>). Upon confirmation of engraftment by bioluminescent imaging (BLI), mice were treated with daily oral Venetoclax for up to 30&#x02009;d (Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9a</xref>). As anticipated, Venetoclax exposure was associated with limited disease control in 697<sup><italic>WT</italic></sup> cells (Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9b, c</xref>) resulting in a small, but significant, prolongation of post-transplant overall survival (OS), with all Venetoclax-treated 697<sup><italic>WT</italic></sup> recipient animals succumbing within 15&#x02009;d of treatment (median OS 19 vs. 22&#x02009;d, <italic>p</italic>&#x02009;=&#x02009;0.0011) (Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9f</xref>). 697<sup><italic>KI</italic></sup> recipient mice treated with vehicle control succumbed to disease slightly later than 697<sup><italic>WT</italic></sup>, potentially reflecting the proliferation defect characterized in-vitro (median OS 25 vs. 19&#x02009;d, <italic>p</italic>&#x02009;=&#x02009;0.0004) (Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9f</xref>). Nevertheless, all vehicle-treated 697<sup><italic>KI</italic></sup> mice succumbed by 19&#x02009;d of treatment. Venetoclax-treated mice engrafted with 697<sup><italic>KI</italic></sup> cells demonstrated markedly improved disease control, as assessed by BLI (Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9d, e</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9c, d</xref>). Only one Venetoclax-treated 697<sup><italic>KI</italic></sup> recipient succumbed to disease within the treatment window, with the remaining 5 recipients gaining up to 2 weeks of survival after cessation of Venetoclax exposure (median OS 47 vs. 25&#x02009;d, <italic>p</italic>&#x02009;=&#x02009;0.0006) (Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9f</xref>).<fig id="Fig9"><label>Fig. 9</label><caption><title>Genetic or pharmacological inhibition of CREBBP sensitizes B-ALL to Venetoclax in-vivo<italic>.</italic></title><p><bold>a</bold> Schema of 697<sup><italic>WT</italic></sup> vs. 697<sup><italic>KI</italic></sup> in vivo drug dosing protocol. NSG mice were intravenously injected with 697<sup><italic>WT</italic></sup> vs. 697<sup><italic>KI</italic></sup> luciferase-expressing cell lines. At 8 days post injection animals were administered Venetoclax (100&#x02009;mg/kg) or vehicle control by oral gavage. Mice were imaged by BLI as indicated. <italic>n</italic>&#x02009;=&#x02009;6 per group. Created in BioRender. Huntly, B. (2025) <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/7ikpp8s">https://BioRender.com/7ikpp8s</ext-link>. <bold>b</bold> Representative BLI images of mice engrafted with 697<sup><italic>WT</italic></sup> cells at days 11 and 17 of treatment. <italic>n</italic>&#x02009;=&#x02009;6 mice per group. <bold>c</bold> Average BLI radiance of mice engrafted with 697<sup><italic>WT</italic></sup> cells at days 11 and 17 of treatment (log p/s/cm<sup>2</sup>/sr). Mean&#x02009;&#x000b1;&#x02009;SEM. <italic>n</italic>&#x02009;=&#x02009;6 mice per group. <bold>d</bold> Representative BLI images of mice engrafted with 697<sup><italic>KI</italic></sup> cells at days 11, 17 and 21 of treatment. <italic>n</italic>&#x02009;=&#x02009;6 mice per group. <bold>e</bold> Average BLI radiance of mice engrafted with 697<sup><italic>KI</italic></sup> cells at days 11, 17 and 21 of treatment (log p/s/cm<sup>2</sup>/sr). Mean&#x02009;&#x000b1;&#x02009;SEM. Vehicle (<italic>n</italic>&#x02009;=&#x02009;5) and Venetoclax treated (<italic>n</italic>&#x02009;=&#x02009;6). <bold>f</bold> Overall survival of NSG mice engrafted with 697<sup><italic>WT</italic></sup> vs. 697<sup><italic>KI</italic></sup> B-ALL cells treated with oral Venetoclax (100&#x02009;mg/kg) or vehicle control. 30 day maximal treatment window is indicated. <italic>n</italic>&#x02009;=&#x02009;6 per group. Significance calculated by Mantel Cox log-rank test. <bold>g</bold> Overall survival of NSG mice engrafted with 697<sup><italic>WT</italic></sup> B-ALL cells treated with oral Inobrodib (20&#x02009;mg/kg) or a combination of Inobrodib (20&#x02009;mg/kg) plus Venetoclax (100&#x02009;mg/kg) (<italic>n</italic>&#x02009;=&#x02009;4 per group). Engraftment control groups were treated with Venetoclax only (<italic>n</italic>&#x02009;=&#x02009;2) or vehicle control (<italic>n</italic>&#x02009;=&#x02009;1). Treatment began at day 8 post-transplant. Significance calculated by Mantel Cox log-rank test. <bold>h</bold> Overall survival of NSG mice engrafted with <italic>CREBBP</italic>-mutated B-ALL high-risk PDX cells orally treated with Vehicle control (black, <italic>n</italic>&#x02009;=&#x02009;5), Inobrodib (20&#x02009;mg/kg) (green, <italic>n</italic>&#x02009;=&#x02009;5), Venetoclax (100&#x02009;mg/kg) (red, <italic>n</italic>&#x02009;=&#x02009;7) or a combination of Inobrodib (blue, 20&#x02009;mg/kg) plus Venetoclax (100&#x02009;mg/kg) (<italic>n</italic>&#x02009;=&#x02009;7). Treatment began at day 77 post-transplant for 3 consecutive days per week for up to 10 weeks. Significance calculated by Mantel Cox log-rank test, **<italic>P</italic>&#x02009;=&#x02009;0.0063; **<italic>P</italic>&#x02009;=&#x02009;0.0024;***<italic>P</italic>&#x02009;=&#x02009;0.0003. Source data are provided as a Source Data file.</p></caption><graphic xlink:href="41467_2025_59531_Fig9_HTML" id="d33e3323"/></fig></p><p id="Par40">We next tested whether co-administration of the orally-available, CREBBP bromodomain inhibitor Inobrodib, which is in early-phase trials in hematological malignancies, could sensitize 697<sup><italic>WT</italic></sup> cells to Venetoclax in-vivo (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9e</xref>). Once-daily oral dosing of single-agent Inobrodib did not confer a survival benefit compared to recipients treated with either vehicle or single-agent Venetoclax. In contrast, recipient mice treated with both agents demonstrated a significant survival advantage (median OS combination 34.5 vs. Inobrodib only 24.5&#x02009;d, <italic>p</italic>&#x02009;=&#x02009;0.0084) (Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9g</xref>).</p><p id="Par41">Finally, we established a PDX from a diagnostic sample obtained from a child with High Hyperdiploid B-ALL, harboring a heterozygous deleterious insertion mutation in <italic>CREBBP</italic>, alongside an <italic>NRAS</italic><sup><italic>G12C</italic></sup> activating mutation, and who responded poorly to treatment, as evidenced by the presence of high-risk measurable residual disease (2.3%) at the end of induction. Engrafted NSG mice were treated with oral Vehicle control, Inobrodib, Venetoclax, or Combination treatment from 77 days after transplant for three consecutive days per week, up to a maximum of 10 weeks. Despite the deleterious <italic>CREBBP</italic> mutation, Inobrodib monotherapy failed to show a significant OS advantage over Vehicle-treated mice (median OS 120 vs. 114&#x02009;d, <italic>p</italic>&#x02009;=&#x02009;0.2) (Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9h</xref>). Conversely, Venetoclax showed a highly significant OS advantage (133 vs. 114&#x02009;d <italic>p</italic>&#x02009;=&#x02009;0.0024), although the majority of animals still succumbed to disease within the 10-week treatment window. In contrast, 6/7 Combination-treated animals survived until the end of the treatment window (161 vs. 114&#x02009;d <italic>p</italic>&#x02009;=&#x02009;0.0003), resulting in a significant OS advantage compared to the Venetoclax only arm (p&#x02009;=&#x02009;0.0063). Histological examination of B-ALL-infiltrated splenic tissue from a separate cohort of mice engrafted with this PDX and that received just two treatment doses showed evidence of 4HNE adducts in the treated mice, consistent with the induction of ferroptosis in vivo (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9f</xref>).</p><p id="Par42">Overall, these findings demonstrate that: (i) oral Venetoclax can be highly efficacious in controlling <italic>CREBBP</italic>-mutated B-ALL in preclinical in-vivo models; and (ii) pharmacological inhibition of CREBBP is a tolerable and effective means of sensitizing B-ALL to Venetoclax in-vivo.</p></sec></sec><sec id="Sec12" sec-type="discussion"><title>Discussion</title><p id="Par43">There is a pressing clinical need to develop novel treatments for patients with high-risk B-ALL, such as those harboring mutations in <italic>CREBBP</italic>. Using a highly-curated panel of clinically-tractable small molecules in an isogenic human cell line model, we demonstrate that <italic>CREBBP</italic> mutation sensitizes cells to Dexamethasone, inhibitors of residual CREBBP/EP300 function and most potently BCL2 inhibition. <italic>CREBBP</italic> LOF profoundly alters metabolism and upon BCL2 inhibition results in ferroptotic cell death, which can be phenocopied by pharmacological CREBBP inhibition in genetically diverse B-ALL cell lines, providing a readily translatable synergistic drug combination for B-ALL more broadly.</p><p id="Par44">Our model shows a number of significant similarities to previously published work. The global transcriptional profile of our <italic>CREBBP</italic>-mutated cells strongly overlaps with those seen in murine <italic>Crebbp</italic><sup>-/-</sup> germinal-center B-cells<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. Other models of <italic>CREBBP</italic>-mutated B-ALL and B-cell lymphoma have implicated changes in cell cycle, metabolism, DNA damage response and apoptosis<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>. We also note that hypodiploid B-ALL, a genetic subtype highly associated with <italic>CREBBP</italic> mutations, has been linked with Venetoclax sensitivity<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. Moreover, preliminary results from an early phase clinical trial of Venetoclax in relapsed pediatric malignancies (NCT03236857) have highlighted responses in high-risk patients, including the small number of <italic>CREBBP</italic>-mutated B-ALL patients enrolled, providing supportive evidence that our results will be clinically translatable<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>.</p><p id="Par45">Our <italic>CREBBP</italic>-mutated model did not show significant differential sensitivity to cytotoxic chemotherapy in the ex-vivo setting. Our cell lines also showed a small but significant sensitization to Dexamethasone, suggesting that <italic>CREBBP</italic> LOF does not significantly alter responses to glucocorticoids<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>. Previous reports have shown variable association of <italic>CREBBP</italic> LOF with chemoresistance in-vitro<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup> and overall, our findings add to a growing body of evidence that CREBBP LOF does not in itself provoke significant cell-intrinsic chemoresistance.</p><p id="Par46">We show that BCL2 inhibition results in ferroptotic cell death in the context of <italic>CREBBP</italic> LOF. Unlike apoptosis, ferroptosis is not mediated by a defined biochemical pathway, rather is the output of a combination of underlying metabolic state, ROS scavenging capacity and lipid composition<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. B-cell progenitors are exquisitely sensitive to redox balance<sup><xref ref-type="bibr" rid="CR45">45</xref></sup> and recent genetic perturbation data has highlighted an underlying propensity for ferroptotic cell death in B-ALL<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. Reflecting its pleiotropic role in biology<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>, how <italic>CREBBP</italic> loss alters this balance is likely to be multifactorial, including by direct transcriptional changes, as well as post translational regulation of proteins affecting metabolism and redox balance. Our functional experiments show significant increases in both glycolytic and mitochondrial metabolism upon CREBBP LOF, associated with enhanced sensitivity to inhibition of ROS scavenging pathways. Thus, in contrast with studies in AML, we show an association between enhanced metabolic state and BCL2 dependence, likely relating to a B-cell-state specific susceptibility to oxidative stress<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR33">33</xref></sup>. Surprisingly, our proteomic analysis identified up-regulation of multiple antioxidant defense pathways, which we hypothesize to be a compensatory adaptation to the enhanced sensitivity to redox stress induced by CREBBP loss of function. Consistent with this, lipidomic analysis of our 697<sup><italic>WT</italic></sup> and 697<sup><italic>KI</italic></sup> cell lines confirmed a significant increase in the number of ferroptosis-predisposing PUFAs in structural membrane lipids upon <italic>CREBBP</italic> mutation. Intriguingly, we also identify a marked lack of ether-linked lipid species, consistent with the transcriptionally-mediated down-regulation of <italic>AGPS</italic> and protein level reduction of GNPAT and ACSL4, accompanied by increased levels of FAR1, which is post-translationally negatively regulated by plasmalogens<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. Concordantly, acquired resistance to Venetoclax is associated with reduced rates of oxidative phosphorylation and transcriptional de-repression of <italic>AGPS</italic>, which would be expected to directly affect plasmalogen biosynthesis<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. Using <italic>CREBBP</italic> expression level as a surrogate for its activity, we also identified highly significant correlations with ROS scavenging pathways and peroxisomal lipid regulators in patients with low <italic>CREBBP</italic> expression. A number of recent papers have linked the enzymatic regulators of plasmalogens to ferroptosis, with variable effects depending on cell type and species studied<sup><xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR39">39</xref></sup>. Our unexpected association of ether-linked lipid dysregulation with ferroptosis susceptibility in B-ALL provides a potential new avenue for further therapeutic investigation.</p><p id="Par47">Lastly, we demonstrate that small molecule inhibition of CREBBP can sensitize genetically-diverse B-ALL cell lines to Venetoclax. This potentially widens the paradigm of our combination to multiple ALL genotypes. Furthermore, the clinically-actionable combination of Venetoclax and Inobrodib was tolerable and highly efficacious in cell lines and PDX in-vivo models. We are aware of preliminary reports of this combination being trialed in other related hematological malignancies<sup><xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR50">50</xref></sup> and propose this as a rational drug combination across a wide range of B-ALL patients.</p></sec><sec id="Sec13"><title>Methods</title><sec id="Sec14"><title>Cell lines</title><p id="Par48">The B-ALL cell lines 697 (ACC 42), REH (ACC 22) and NALM6 (ACC 128) were purchased from DSMZ. RS411, KOPN8 and SUPB15 were provided by Prof. Owen Williams (UCL, UK). 697, REH, KOPN8, RS4-11 were cultured at 37&#x02009;&#x000b0;C with 5% CO2 in IMDM (ThermoFisher, 12440053) supplemented with 10% v/v heat-inactivated fetal bovine serum (HI-FBS) (Sigma Aldrich, F7524), Penicillin-Streptomycin 100U/ml (Sigma Aldrich, P0781) and 1% v/v L-glutamine (Sigma Aldrich, G7513). NALM6 and SUPB15 were cultured in IMDM 20% serum. HEK-293T cells were maintained in DMEM (Sigma D0819), 10% FBS, L-glutamine, and penicillin/streptomycin. Cell lines were tested for mycoplasma by PCR (CSCI Core Facility) and STR genotyped using Promega Powerplex 16-HS kit (performed by Genetica LabCorp). Cells were routinely passaged to 1&#x000d7;10<sup>6</sup>/ml every 2&#x02013;4 days. Venetoclax-resistant 697<sup><italic>WT</italic></sup>and 697<sup><italic>KI</italic></sup> cells were generated over 10 weeks by exposure to increasing concentrations of Venetoclax (Selleckchem, S8048) until stable growth in 2000nM Venetoclax. Resistant cells were washed to remove Venetoclax at least 24&#x02009;h prior to functional experiments.</p></sec><sec id="Sec15"><title>Generation of <italic>CREBBP</italic> Mutant Lines</title><p id="Par49">697 and REH cells were lentivirally-transfected with Cas9, single cell cloned and tested for high Cas9 activity by GFP/BFP reporter assay. <italic>CREBBP</italic><sup><italic>R1446C</italic></sup> gene-editing reagents were introduced by nucleofection (Nucleofector II, Kit R, Lonza) consisting of a gRNA/Cas9 RNP complex (IDT 1072532, 1081060: target sequence CATGGTAAACGGCTGTGCGG), two AltR ssDNA Ultramers silently mutating the PAM sequence with or without insertion of the R1446C mutation (50:50 mix: T*T*CACATACTCTAAATATCCAATAAGGATCTCATGGTAAACGGCTGTGCAGAGACAACGTGGCCGGAAGAAATGAATACTATCCAGATAAGAAATGTA*C*A; T*T*CACATACTCTAAATATCCAATAAGGATCTCATGGTAAACGGCTGTGCGGAGACAACGTGGCCGGAAGAAATGAATACTATCCAGATAAGAAATGTA*C*A), 3&#x02009;mM homology directed repair enhancer (IDT, 1081072) and IDT nucleofection enhancer oligonucleotide (IDT 1075915) according to manufacturer&#x02019;s protocol. At 48&#x02009;h ATTO550<sup>+ve</sup> single cells were FACS sorted into 96-well plates (BD FACSAria Fusion cell sorter) and, upon growth, colonies screened for successful editing by HpyCH4V amplicon digestion (F:GAGCACCTGGAAAGAGGAGC; R:CCCACAGGCGTGTGTACATT). Clones were validated by Sanger sequencing of the bulk screening amplicon and 10xTOPO-TA-cloned PCR products (ThermoFisher, K4575J10).</p></sec><sec id="Sec16"><title>MTS</title><p id="Par50">All drugs were purchased from Selleckchem, except A1155463 (Cayman Chemicals), and reconstituted to 10&#x02009;mM in DMSO. 72-h viability assays were performed using CellTiter 96&#x000ae; AQ<sub>ueous</sub> One Solution Cell Proliferation Assay (Promega, G3580) following manufacturer recommendations and 490&#x02009;nM absorbance measured using a CLARIOstar plate reader (BMG Labtech). Drug synergy scores were calculated using SynergyFinder web tool (<ext-link ext-link-type="uri" xlink:href="https://synergyfinder.fimm.fi">https://synergyfinder.fimm.fi</ext-link>)<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. We defined a peak ZIP threshold of +10 for synergism.</p></sec><sec id="Sec17"><title>Mitochondrial depolarization using JC1</title><p id="Par51">Mitochondrial depolarization was assessed on cells exposed to Venetoclax for 24&#x02009;h using the MitoProbe<sup>TM</sup> JC-1 assay kit (ThermoFisher, M34152) following manufacturer recommendations. Cells were analysed by flow cytometry (BD Fortessa) for 488nm-excitied 530/30 filter signal. Viable cells were gated by DAPI (BD, 564907) exclusion. During flow cytometry cells were routinely handled in DPBS (Gibco, 14190-094) 2% HI-FBS and 2&#x02009;mM EDTA (Invitrogen, 15575038).</p></sec><sec id="Sec18"><title>Annexin-V staining by flow cytometry</title><p id="Par52">Annexin-V externalization was assessed using anti-AnnexinV-APC kit from (eBioscience<sup>TM</sup> 88-8007-74) following manufacturer protocol. Briefly, after incubation with drug/vehicle, cells were washed in DPBS, resuspended in Annexin binding buffer and incubated with 1/40 Annexin-V-APC dilution for 15&#x02009;min at room temperature (RT) in the dark. Cell pellet was resuspended in 7-AAD (BD, 559925) diluted 1/100 in 1x binding buffer and analyzed by flow cytometry.</p></sec><sec id="Sec19"><title>Western blot</title><p id="Par53">Protein lysates were obtained from 1&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells after resuspending the pelleted cells in 50&#x02009;&#x000b5;l boiling lysis buffer (31&#x02009;mg/ml DTT, 10% SDS, 10% Glycerol, 1% Bromophenol blue and 12.5% 1MTris-HCL) or RIPA buffer (50&#x02009;mM Tris pH8, 1&#x02009;mM EDTA 0.5&#x02009;M, 150&#x02009;mM NaCl 5&#x02009;M, 1% NP40(10%), 0.1% SDS(20%) and 0.5% DOC). RIPA buffer lysates were resuspended in boiling loading control with DTT (Cell Signaling Technology, 7722). Cell lysates were separated by SDS-PAGE electrophoresis (NuPAGE 3&#x02013;8%TRIS acetate protein gels (Invitrogen) or 4-20% Mini-PROTEAN TGX protein gel (Bio-Rad)). Precision-plus protein dual color ladder (Bio-Rad, #1610374) or HiMark&#x02122; Pre-stained Protein Standard (Invitrogen, LC5699) were used as a size marker. Proteins were transferred to a methanol pre-activated membrane (Merck, IPFL00010) and then blocked with 5% BSA (ThermoFisher, BP1600) or powdered milk in TBS-0.05% Tween20 (TBST) before proceeding to antibody staining. Primary and secondary antibodies were diluted in 5% BSA or milk in TBST. Primary antibodies were incubated overnight at 4<sup>o</sup>C or 1&#x02009;h at RT; secondary antibodies were incubated for 1&#x02009;h at RT. Washes were performed with TBST. Membrane fluorescence was acquired using Odyssey imager (LI-COR).</p><p id="Par54">Antibodies used: Caspase 3/PARP (Abcam, Ab136812, 1/250), BCL2 (E17) (Abcam, ab32124, Lot: GR3232704-4, 1/1000), &#x003b2;-Tubulin (Sigma-Aldrich, T8328, 1/2000), 4HNE (Abcam, ab46545, Lot: 1073022-2, 1/1000), GPX4 (Abcam, ab41787, Lot: 1047829-4, 1/1000), CREBBP (A22) (Santa Cruz biotechnology, SC369, Lot: G1613, 1/500) and Vinculin (H-10) (Santa Cruz biotechnology, sc25336, Lot: I2718, 1/250).</p></sec><sec id="Sec20"><title>Lentiviral production</title><p id="Par55">Lentiviral vectors were produced in HEK-293T cells by co-transfection of the previously sequenced vector constructs with psPAX and pMDG.2 packaging plasmids using Trans-IT LT-1 (Mirus, MIR2700). HEK293T cells were incubated overnight at 37&#x02009;&#x000b0;C and the next day medium was changed for IMDM 10% HI-FBS. Viral particles were harvested at 48 and 72&#x02009;h by centrifugation and 45&#x003bc;m filtration. 250&#x02009;&#x000b5;l of viral particles were used to transfect 1x10<sup>6</sup> B-ALL cells by spinoculation (900&#x02009;g for 2&#x02009;h at 32&#x02009;&#x000b0;C) in the presence of 10&#x02009;&#x003bc;g/ml Polybrene (sc-134220). Subsequently, the cultures were diluted in fresh media and washed three times the following morning.</p><p id="Par56">Transfection efficiencies were assessed by flow cytometric reporters and transfected cells selected using either 0.5&#x02009;&#x003bc;g/ml of Puromycin (Gibco) for three days or FACS cell sorting as appropriate to achieve &#x0003e;90% transfection.</p></sec><sec id="Sec21"><title>shRNA Knockdown of <italic>BCL2</italic></title><p id="Par57">Doxycycline-inducible reported shRNA knockdown constructs (pLT3GEPIR_GFP/Cherry_Stuffer) were provided by Dr Thomas Mercher (originally from Prof Johannes Zuber), <italic>EcoRI/XhoI</italic> double digested and the vector backbone purified by gel purification as previously described<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. <italic>BCL2</italic> targeting shRNAs were synthesized as Ultramers (IDT) based on the following recommended sequences (BCL2_1: TGCTGTTGACAGTGAGCGCCCGGGAGATAGTGATGAAGTATAGTGAAGCCACAGATGTATACTTCATCACTATCTCCCGGTTGCCTACTGCCTCGGA; BCL2: TGCTGTTGACAGTGAGCGCGAGGATCATGCTGTACTTAAATAGTGAAGCCACAGATGTATTTAAGTACAGCATGATCCTCTTGCCTACTGCCTCGGA; Renilla: TGCTGTTGACAGTGAGCGCAGGAATTATAATGCTTATCTATAGTGAAGCCACAGATGTATAGATAAGCATTATAATTCCTATGCCTACTGCCTCGGA)<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. Complementary oligonucleotides were resuspended to 500&#x02009;ng/&#x000b5;l, boiled and hybridized, ligated using T4 ligase (NEB) (5&#x02009;ng insert:50&#x02009;ng vector) and transformed into chemically-competent <italic>E. coli</italic>. Bacterial colonies were screened by PCR (F:CTCGACTAGGGATAACAGGG R:CAAAGAGATAGCAAGGTATTCAG) and successful plasmid clones miniprepped (Qiagen) and sequence verified by Sanger sequencing. Cells were selected with puromycin 0.5&#x02009;&#x003bc;g/ml. Cells were incubated with 500&#x02009;ng/ml of doxycycline and mCherry positive cells FACS sorted to confirm knock-down by qPCR and western blot.</p><p id="Par58">Competitive co-culture assays were performed by mixing an equal number of <italic>renilla</italic> shRNA-GFP and one of two <italic>BCL2</italic> shRNA-mCherry transfected 697<sup><italic>WT</italic></sup> or 697<sup><italic>KI</italic></sup> cells in triplicate. <italic>BCL2</italic> knockdown was induced with doxycycline and aliquots of cell culture analyzed daily by flow cytometry. Results are presented as the ratio of 697<sup><italic>KI</italic></sup> Cherry:GFP events normalized to the mean ratio of 697<sup><italic>WT</italic></sup> Cherry:GFP events.</p></sec><sec id="Sec22"><title>Gene expression by reverse transcriptase quantitative PCR (RT-qPCR)</title><p id="Par59">Total RNA was extracted using the RNeasy kit (Qiagen) and 1&#x02009;&#x003bc;g was used to synthesize cDNA using TaqMan Reverse transcription (Applied Biosystems, N8080234) following manufacturer&#x02019;s instructions. RT-qPCR was carried out with SYBR Green PCR master mix (Agilent, 600882) on cDNA (diluted 1:5 in water). The expression level of RNA was calculated using the standard curve method, normalized to the expression of <italic>GAPDH</italic>. Primer pairs: <italic>BCL2</italic>F:ATTGGGAAGTTTCAAATCAGC; <italic>BCL2</italic>R:TGCATTCTTGGACGAGGG; <italic>GAPDH</italic>F:CCACATCGCTCAGACACCAT; <italic>GAPDH</italic>R:CCAGGCGCCCAATACG.</p></sec><sec id="Sec23"><title>Cell cycle analysis by FUCCI reporter</title><p id="Par60">CSII-EF-MCS vectors encoding mCherry-hCdt1(30/120) and mVenus-hGeminin(1/110) were obtained from Atsushi Miyawaki, RIKEN BioResource Research Center<sup><xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR53">53</xref></sup>. Lentiviral vectors were made and dual transfected into 697 isogenic cell lines as above. mCherry/mVenus dual-positive cells were enriched by FACS cell sorting (BD Influx) to generate high-expressing stable cell lines and analyzed by flow cytometry.</p></sec><sec id="Sec24"><title>Seahorse metabolic assays</title><p id="Par61">Oxphos and glycolysis assays were performed using the Seahorse XFe96 analyser (Agilent) according to manufacturer&#x02019;s instructions. Briefly, cells were analysed at 48-72&#x02009;h post passage and in drug concentrations/DMSO vehicle as stated in figure legends. For glycostress experiments, cells were harvested and counted in Seahorse XF base medium, pH7.4 supplemented with 2mM L-Glutamine (Sigma Aldrich, G7513). The final concentration of the injected drugs in the glycostress test is 10&#x02009;mM glucose (Sigma, G7021), 1&#x02009;&#x000b5;M Oligomycin A and 50&#x02009;mM of 2-deoxyglucose (2-DG) (Sigma, D3179). For mitostress tests, Seahorse XF base media was supplemented with 2mM L-Glutamine, 10&#x02009;mM Glucose and 1&#x02009;mM Sodium pyruvate (Sigma, S8636). The final concentration of the injected drugs was 1&#x02009;&#x000b5;M Oligomycin, 1&#x02009;&#x000b5;M FCCP supplemented with 1&#x02009;&#x000b5;M Sodium pyruvate and 1&#x02009;&#x000b5;M Antimycin. For experiments using Venetoclax or A485 pretreatment drug exposure continued in the Seahorse media. Cells were plated at a density of 70000 cells/well in XFp tissue culture plates previously coated with CellTak (Corning, 354240) and incubated for 45&#x02009;mins at 37 &#x000b0;C in a CO2-free incubator prior to analysis. Seahorse experiments were performed with multiple biological replicates on at least two separate occasions to account for technical failures or gross outliers, which were excluded based on the independent judgment of two researchers.</p></sec><sec id="Sec25"><title>Lipid peroxidation assays</title><p id="Par62">Lipid peroxidation was assessed using the lipid peroxidation sensor BODIPYC<sub>11</sub>-581/591 (ThermoFisher, D3861) according to manufacturer&#x02019;s instructions. Briefly, cells were washed in DPBS and stained with 4&#x02009;&#x000b5;M BODIPY dye for 30&#x02009;min at 37&#x02009;&#x000b0;C with gentle shaking in the dark. After washing with DPBS, cells were analyzed by flow cytometry. Replicate data is presented as the ratio of 488nm-excited 530/30 (FL1) to 610/20 (FL3) filtered signal.</p></sec><sec id="Sec26"><title>Proteomics</title><p id="Par63">Pellets were lysed in a buffer containing 100&#x02009;mM triethylammonium bicarbonate (TEAB) (Sigma, #T4708), 1% sodium deoxycholate (SDC), 10% isopropanol, 50&#x02009;mM NaCl, protease and phosphatase inhibitors (Halt, #78441) and universal nuclease (Pierce, #88700), and the protein concentration was measured with Bradford assay (Bio-Rad, Quick Start<sup>TM</sup>). 100&#x02009;&#x000b5;g total protein per sample were reduced and alkylated simultaneously by adding tris-2-carboxyethyl phosphine (&#x003a4;CEP, Sigma) at a final concentration of 5&#x02009;mM, and freshly prepared iodoacetamide at a final concentration of 10&#x02009;mM followed by 1&#x02009;h incubation at RT in the dark. Then, the samples were digested overnight at 37&#x02009;&#x000b0;C with trypsin (Pierce #90058) and peptides were labeled with the TMTpro-16plex reagents according to manufacturer&#x02019;s instructions (Thermo Scientific). The TMT mixture was fractionated on a Dionex UltiMate 3000 system at high pH using the X-Bridge C18 column (3.5&#x003bc;m 2.1x150mm, Waters). Twenty-two <ext-link ext-link-type="uri" xlink:href="https://www.thermofisher.com/order/catalog/product/A44520">https://www.thermofisher.com/order/catalog/product/A44520</ext-link> fractions were collected and 10% was transferred on different tubes for the TMT whole-proteome analysis.</p><p id="Par64">Whole proteome analyses were performed on a Dionex UltiMate 3000 UHPLC system coupled with the nano-ESI Fusion-Lumos (Thermo Scientific) mass spectrometer. The MS2 scans were performed in the ion trap with collision energy 32%. Peptides were isolated in the quadrupole with isolation window 0.7 Th. The 10 most intense fragments were selected for Synchronous Precursor Selection (SPS) HCD-MS3 analysis with MS2 isolation window 2.0 and HCD collision energy 50%. Raw files were processed with the SequestHT search engine on Proteome Discoverer 2.4 software. The SequestHT node included the following parameters: Precursor Mass Tolerance 20 ppm, Fragment Mass Tolerance 0.5&#x02009;Da for the CID spectra and 0.02&#x02009;Da for the HCD spectra, Dynamic Modifications were Oxidation of M (&#x02009;+&#x02009;15.995&#x02009;Da), Deamidation of N, Q (&#x02009;+&#x02009;0.984&#x02009;Da) and Static Modifications were TMTpro at any N-Terminus, K (&#x02009;+&#x02009;304.207&#x02009;Da) and carbamidomethyl at C (&#x02009;+&#x02009;57.021). Only unique peptides filtered for FDR&#x02009;&#x0003c;&#x02009;1% were used for quantification and the consensus workflow included calculation of TMT signal-to-noise.</p><p id="Par65">Data processing, normalization, and statistical analysis of peptide intensities were performed using the qPLEXanalyzer package from Bioconductor (cite: <ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/s41467-018-04619-5">https://www.nature.com/articles/s41467-018-04619-5</ext-link>). Peptide intensities were normalized using median scaling. Protein-level quantification was then determined by summing the normalized peptide intensities. A statistical analysis of differentially regulated proteins was subsequently conducted using the two-sided limma statistical test. To control for the false discovery rate (FDR), <italic>p</italic> values were adjusted using the Benjamini-Hochberg method for multiple testing correction.</p></sec><sec id="Sec27"><title>Lipidomics</title><p id="Par66">Lipids were extracted using the protein&#x02011;precipitation liquid extraction protocol has been described previously<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. At each pellet of cells, 650&#x02009;&#x000b5;L of Chloroform, 100&#x02009;&#x000b5;L of Lipids internal standard (5&#x02009;&#x000b5;M in methanol) was added. Then 250&#x02009;&#x000b5;L of methanol was added to each sample and finally 400&#x02009;&#x000b5;L of acetone was added. The samples were vortexed for 60&#x02009;s and then centrifuged for 10&#x02009;min. The single-phase supernatant was transferred in other multiwall plate. The extract (~1.4&#x02009;mL) of each sample was dried using gentle flow of N<sub>2</sub> at 60 &#x000b0;C. The samples were reconstituted in 100&#x02009;&#x000b5;L of 2:1:1 (propan-2-ol, acetonitrile and water, respectively) then thoroughly vortexed. The samples were analysed using LC-MS, with reversed phase chromatography and high-resolution mass spectrometry in both positive and negative mode electrospray ionization. Full chromatographic separation of the lipids was performed using a Waters HPLC system. 10&#x02009;&#x000b5;L of sample extraction was injected onto a Waters Acquity UPLC CSH C18 column (1.7&#x02009;&#x000b5;m, I.D. 2.1&#x02009;mm&#x02009;&#x000d7;&#x02009;50&#x02009;mm), maintained at 55&#x02009;&#x000b0;C. Two mobile phase have been used: mobile phase A consists of acetonitrile, and water 6:4 with 10&#x02009;mM ammonium formate; mobile phase B consists of propan-2-ol, and acetonitrile 9:1, with 10&#x02009;mM ammonium formate. The flow was maintained at 500&#x02009;&#x000b5;L per minute through the gradient<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>.</p><p id="Par67">The raw data was processed using MS-DIAL software (version 4.9). This process included peak selection, alignment and data annotation<sup><xref ref-type="bibr" rid="CR55">55</xref></sup> (see Supplementary Data Table&#x000a0;<xref rid="MOESM5" ref-type="media">3</xref> for parameters). The database of the lipid was validated against Lipid Maps (<ext-link ext-link-type="uri" xlink:href="http://www.lipidmaps.org/tools/ms">http://www.lipidmaps.org/tools/ms</ext-link>). The annotation of lipid molecular species was performed using the accurate mass data acquired with mass spectrometry (MS) and specific retention time acquired from the liquid chromatography. Lipid semi-quantification was performed using the deuterated internal standard for each lipid class and was based on the known concentrations of the standards added to the samples (Supplementary Data Table&#x000a0;<xref rid="MOESM5" ref-type="media">3</xref>). At the end of this analytical step, a set of matrices was produced containing the expressive concentrations in nmol/1 million cells of the lipid molecular species previously annotated. For the lipidomic data analysis and data matrices preparation LipidOne 2.0 web-platform was utilized<sup><xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR57">57</xref></sup>.</p></sec><sec id="Sec28"><title>RNA sequencing library preparation</title><p id="Par68">697<sup><italic>WT</italic></sup> and 697<sup><italic>KI</italic></sup> treated with 20&#x02009;nM Venetoclax or DMSO vehicle for 24&#x02009;h (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>) or 697<sup><italic>WT</italic></sup>, 697<sup><italic>KI</italic></sup>, 697<sup><italic>WT</italic>-VenR</sup> or 697<sup><italic>KI</italic>-VenR</sup> cells removed from Venetoclax for 24&#x02009;h (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>) were harvested, washed and RNA was extracted from 4&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells using the RNeasy kit (Qiagen) (performed in biological triplicate). Libraries were prepared using NEBNext Poly(A) mRNA magnetic Isolation module (NEB, E7490) starting with 1&#x02009;&#x000b5;g DNA-free RNA, as per manufacturer&#x02019;s instructions. RNA fragmentation, double-strand cDNA synthesis, end repair, adapter ligation and PCR amplification (9 cycles) was performed using NEBNext Ultra II directional RNA library prep kit for Illumina protocol (NEB, E7760) according to manufacturer&#x02019;s protocol. Library quality and molarity was measured by Qubit (ThermoFisher) and TapeStation (Agilent). Samples were 50-bp paired-end sequenced on the NovaSeq (Illumina) instrument (CRUK CI Genomics Core Facility).</p></sec><sec id="Sec29"><title>RNAseq analysis</title><p id="Par69">The quality of the paired-end RNA-seq reads were assessed using FastQC (<ext-link ext-link-type="uri" xlink:href="https://www.bioinformatics.babraham.ac.uk/projects/fastqc/">https://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link>). All RNA-seq libraries were found to be above the minimum quality thresholds across quality control metrics. Adapter sequences were trimmed using TrimGalore package (<ext-link ext-link-type="uri" xlink:href="https://github.com/FelixKrueger/TrimGalore">https://github.com/FelixKrueger/TrimGalore</ext-link>), and were next mapped against the human genome version 38 (Hg38) using STAR Version=2.7.10a<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>. Only uniquely-mapping high confidence reads (flags NH:i:1 and MAPQ&#x02009;=&#x02009;255) were retrieved and used for transcriptome quantification with featureCounts version 2.0.1<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>. Genes with a minimum of 10 reads or more in a minimum of two samples were considered for all downstream analysis. Differential expression analysis was based on either a single factor model (&#x02009;~&#x02009;genotype/treatment/sensitivity) or an interaction model when two factors were considered (&#x02009;~&#x02009;genotype * treatment), and the interaction term was used to determine the difference of the effect of treatment across genotypes. The interaction model was chosen over the additive model for two-factor analysis of differential expression based on the clustering of normalized RNA-seq libraries on a PCA plot and the number of statistically significant differentially-expressed genes across both models using likelihood-ratio test (LRT). Differential expression analysis was conducted using gene level transcriptomic reads using the Bioconductor package DESeq2<sup><xref ref-type="bibr" rid="CR60">60</xref></sup>. KEGG Pathway enrichment, Gene Set Enrichment Analyses (GSEA) and Gene Ontology (GO) Analyses were all performed using the R package &#x02018;clusterProfiler&#x02019; version 4.4.4<sup><xref ref-type="bibr" rid="CR61">61</xref></sup>. A minimum <italic>p</italic> value (corrected for multiple testing) and FDR of 0.05 were used across all tests to establish statistical significance.</p><p id="Par70">The correlation of <italic>CREBBP</italic> expression in human patients with genes/pathways of interest was based on the RNA-seq cohort of B-ALL patients from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Phase II initiative (<ext-link ext-link-type="uri" xlink:href="https://www.cancer.gov/ccg/research/genome-sequencing/target">https://www.cancer.gov/ccg/research/genome-sequencing/target</ext-link>)<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. Reads-per-kilobase-million (RPKM) normalized reads from 203 patients were obtained from TARGET&#x02019;s Genomic Data Commons (<ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov">https://portal.gdc.cancer.gov</ext-link>) portal along with associated clinical and sample metadata. The median average expression of all genes in pathways of interest was compared with <italic>CREBBP</italic> expression for each patient, and the results were collated for correlation across all patients. All <italic>p</italic> values were corrected for multiple-testing using the Bonferroni formula.</p></sec><sec id="Sec30"><title>ChIP-Seq/CUTandRUN</title><p id="Par71">7 million 697<sup><italic>WT</italic></sup> and 697<sup><italic>KI</italic></sup> were cross-linked with 1% formaldehyde for 10&#x02009;min at RT, reaction that was stopped by Glycine (final concentration 125&#x02009;mM). Cells were washed twice with ice-cold PBS and finally resuspended in cold PBS with 1x Protease inhibitors (PI) (Roche, 11836170001). After this step all buffers contained PI. Cell pellets were lysed with cell lysis buffer (10&#x02009;nM Tris-Cl, 10&#x02009;mM NaCl, 0.2% NP40) for 10&#x02009;min at 4&#x02009;&#x000b0;C. After centrifugation at 2400&#x02009;rpm at 4&#x02009;&#x000b0;C, nuclei were resuspended in 100&#x02009;&#x000b5;l of Sonication buffer (0.5% SDS, 20&#x02009;mM Hepes, 5&#x02009;mM EDTA) and incubated on ice for 10&#x02009;min. Chromatin was sheared by sonication (three cycles of 30&#x02009;s ON and 30&#x02009;s OFF). Prior to immunoprecipitation, the sonicated chromatin was diluted with 400&#x02009;&#x000b5;l of dilution buffer (20&#x02009;mM Tris pH8.1, 2&#x02009;mM EDTA, 150&#x02009;mM NaCl, 1% TritonX100 and 0.01% SDS). Immunoprecipitation was performed overnight in 20% Tx-100 using 2.5&#x02009;&#x000b5;g of antibody (IgG, Proteintech, 30000-0-AP; H3 (1B1B2), Cell Signaling Technology, 14269S and H3K27ac, Active motif, 39133). Immunocomplexes were captured using the protein A (10002D) and protein G (10004D) Dynabeads (Invitrogen). After 4&#x02009;h, the immunocomplexes were magnetized and repeatedly washed in the following buffers: RIPA buffer (20&#x02009;mM Hepes, 150&#x02009;mM NaCl, 1&#x02009;mM EDTA, 0.1% SDS, 1% Tx-100), RIPA-500 (20&#x02009;mM Hepes, 500&#x02009;mM NaCl, 1&#x02009;mM EDTA, 0.1% SDS, 1% Tx-100, 0.1% DOC) and LiCl wash buffer (10&#x02009;mM Tris-HCl, 1&#x02009;mM EDTA, 150&#x02009;mM LiCl, 0.5% NP40, 0.5% DOC).</p><p id="Par72">To perform reverse crosslinking, ChIP samples were incubated overnight at 65&#x02009;&#x000b0;C with ChIP elution buffer (10&#x02009;mM Tris-HCl, 5&#x02009;mM EDTA, 300&#x02009;mM NaCl, 0.4% SDS) with 2&#x02009;&#x000b5;l of Proteinase K (Thermo Scientific EO0491). Samples were cleaned up using a Qiagen PCR Minelute column.</p><p id="Par73">To perform CUTandRUN, 0.3 million cells per sample of 697<sup><italic>WT</italic></sup> and 697<sup><italic>KI</italic></sup> cell lines were harvested and washed in wash buffer (20&#x02009;mM HEPES, 150&#x02009;mM NaCl, 0.5&#x02009;mM Spermidine, 1x cOmplete<sup>TM</sup> EDTA-free PI). Cells were incubated for 10&#x02009;min at RT with activated Concavalin A beads (EpiCypher, 21-1401). The suspension was magnetized, supernatant removed and the cells were resuspended in 1&#x02009;&#x000b5;g of the corresponding antibody (CREBBP, Santa cruz technologies, sc369(A22), lot: G1613; IgG, Epicypher, cat 13-0042) diluted in antibody buffer (wash buffer plus 0.01% digitonin and 2&#x02009;mM EDTA) on a nutator overnight at 4&#x02009;&#x000b0;C. After incubation, the suspension was magnezited and beads were washed and finally resuspended with digitonin buffer (wash buffer plus 0.01% digitonin) prior to the 10&#x02009;min incubation of the nuclei with CUTANA pAG-MNase (EpiCypher, 15-1016). Beads were washed again with digitonin buffer and the targeted chromatin was digested and released with the addition of 100&#x02009;mM CaCl<sub>2</sub> that activates the MNase tethered to chromatin. After 2&#x02009;h at 4&#x02009;&#x000b0;C, stop buffer (40&#x02009;mM NaCl, 20&#x02009;mM EDTA, 4&#x02009;mM EGTA, 50&#x02009;&#x000b5;g/ml RNase A and 50&#x02009;&#x000b5;g/ml Glycogen) was added. Cleaved DNA was purified using the Monarch PCR DNA clean up kit (NEB).</p><p id="Par74">Library preparation was performed using the NEBNext Ultra II DNA library preparation kit for Illumina (NEB, E7645) according to manufacturer&#x02019;s protocol. Library quality and molarity was measured by Qubit (ThermoFisher) and TapeStation (Agilent). Samples were 50-bp paired-end sequenced on the NovaSeq (Illumina) instrument (CRUK CI Genomics Core Facility).</p></sec><sec id="Sec31"><title>ChIP-Seq/CUTandRUN analysis</title><p id="Par75">Sequencing libraries that passed the minimum quality requirements, as determined by the quality metrics of the tool FastQC (<ext-link ext-link-type="uri" xlink:href="https://www.bioinformatics.babraham.ac.uk/projects/fastqc/">https://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link>), were considered for downstream analysis and processed using either the ChIP-seq or CUTandRUN pipelines. For ChIP-seq libraries, paired end reads were first trimmed for Trueseq adaptors using trimmomatic<sup><xref ref-type="bibr" rid="CR62">62</xref></sup> (version 0.36) with the following parameters (PE -phred33 ILLUMINACLIP:Truseq3.PE.fa:2:15:4:4:true LEADING:20 TRAILING:20 SLIDINGWINDOW:4:15 MINLEN:25). Adaptor-trimmed reads were then aligned to the human genome version hg38 using Bowtie 2<sup><xref ref-type="bibr" rid="CR63">63</xref></sup> (version 2.4.5) using the following parameters (--very-sensitive-local --phred33 -I 10 -X 700). Aligned reads in SAM format were converted to BAM format, sorted then indexed using Samtools<sup><xref ref-type="bibr" rid="CR64">64</xref></sup> (version 1.11). Duplicate reads in aligned BAM files were marked using the Picard tool MarkDuplicates, and the resulting duplicate reads were subsequently removed by Samtools. The aligned, de-duplicated read files were converted to BigWig files for genome browser visualization and analysis of co-occupancy with CREBBP libraries using the bamCoverage function of the deeptools<sup><xref ref-type="bibr" rid="CR65">65</xref></sup> (version 3.5.1), normalizing by counts-per-million (CPM) and a bin size of 10. CUTandRUN libraries were processed using the CUT&#x00026;RUNTools pipeline (available at: <ext-link ext-link-type="uri" xlink:href="https://github.com/fl-yu/CUT-RUNTools-2.0">https://github.com/fl-yu/CUT-RUNTools-2.0</ext-link>)<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>, using the same human reference genome version (hg38). We ran the pipeline without spike-in controls, or filtering for short fragments (&#x02009;&#x0003c;&#x02009;120&#x02009;bp) to maximize the capture of CREBBP binding.</p><p id="Par76">Genomic occupancy of CREBBP/H3K27ac were established by peak-calling against matched input controls using the PCR-duplicate filtered, aligned paired-end BAM files from the ChIP-seq and the CUT&#x00026;RUNTools pipeline. MACS2<sup><xref ref-type="bibr" rid="CR67">67</xref></sup> (version 2.2.7.1) was used to call peaks with the callpeak function and the following parameters (-p 0.05 -B --SPMR --keep-dup all). Black-listed regions were subsequently removed from the called peaks using bedops<sup><xref ref-type="bibr" rid="CR68">68</xref></sup> (version 2.4.41) and a list of version-specific blacklisted region list from the human genome. Peaks with a minimum q-value of 0.05 were utilized for all downstream analysis.</p><p id="Par77">CREBBP and H3K27ac were annotated to their associated genes by their proximity to transcription start sites (TSSs) using the R package ChIPseeker<sup><xref ref-type="bibr" rid="CR69">69</xref></sup>. Promoter regions were defined as the &#x000b1;3&#x02009;kb window around TSSs, with any region acetylated by H3K27ac outside of that window and within a&#x02009;&#x000b1;&#x02009;100&#x02009;kb window of a TSS as an enhancer element. Co-occupancy of CREBBP and H3K27ac was determined by intersecting the two peak sets using the R package IntersectionSet<sup><xref ref-type="bibr" rid="CR70">70</xref></sup>, and the Venn diagrams of those intersection were generated using the R package eulerr.</p><p id="Par78">Profile plots showing genomic signal enrichment of simultaneous CREBBP/H3K27ac occupancy around TSSs of differentially expressed genes from the RNA-seq experiments of 697<sup><italic>WT</italic></sup> vs. 697<sup><italic>KI</italic></sup> were generated using scores calculated by the computeMatrix function of the deeptools package with the parameters (--binSize 10 --skipZeros). Score files inputs (in BigWig format) for this analysis were generated by converting the total BigWig signal files from the ChIP-seq/CUTandRUN pipelines to Wig format using bigWigToWig from the UCSC utilities<sup><xref ref-type="bibr" rid="CR71">71</xref></sup>, then converted to BED format using wig2bed from bedops, followed by selecting those regions that were established to be common between 697<sup><italic>WT</italic></sup> vs. 697<sup><italic>KI</italic></sup> or those with co-bound CREBBP-H3K27ac sites in the previous step, and saved as bedgraph files, to be converted next to BigWig again using bedGraphToBigWig from the UCSC utilities.</p><p id="Par79">The integration of CREBBP binding with the differential gene expression data from 697<sup><italic>WT</italic></sup> vs. 697<sup><italic>KI</italic></sup> to deduce co-regulation of target genes was done using the Binding and Expression Target Analysis (BETA) package<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. For 697<sup><italic>KI</italic></sup>, the entire list of expressed genes with the adjusted <italic>p</italic> values and log2 fold-change of the difference of their expression to their 697<sup><italic>WT</italic></sup> counterparts, along with the list of CREBBP-H3K27ac enhancer-associated peak regions, were used as input for the BETA plus function with the following parameters (-g hg38 --df 0.05 --da 1 --mn 10). The same analysis was repeated for the 697<sup><italic>WT</italic></sup>, but with reversing the signs for the log2 fold-change in gene expression values to account for the directionality in differential gene expression.</p></sec><sec id="Sec32"><title>In-vivo dosing studies</title><p id="Par80">All experiments were conducted under a UK Home Office project (under the Animals (Scientific Procedures) Act 1986, Amendment Regulations (2012)) and following ethical review by the University of Cambridge Animal Welfare and Ethical Review Body. Primary patient samples for PDX derivation were supplied by the VIVO Biobank (REC reference 23/EM/0130). Parental consent was obtained and no compensation provided.</p><p id="Par81">For the in-vivo dosing experiments in Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9a&#x02013;f</xref>, 0.25&#x02009;&#x000d7;&#x02009;10<sup>6</sup> luciferase expressing cells (isogenic cell lines 697<sup><italic>WT</italic></sup> &#x00026; 697<sup><italic>KI</italic></sup>) were injected by tail vein injection into sub-lethally (2&#x02009;Gy) irradiated 13-15 week-old female NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice. Mice received a daily dose of Venetoclax (100&#x02009;mg/kg)(LC Labs) or vehicle control (15% Kolliphor HS15 (Sigma 42966), 60% Phosal propylene glycol (MP, 151957) and 10% ethanol), by means of Oral Gavage (FTP-20-30, INSTECH) for thirty days or until the experimental endpoints were reached. Disease progression was tracked by IVIS bioluminescence imaging (PerkinElmer); in brief, D-luciferin (Perkin Elmer, 122799) was administered by intraperitoneal (IP) injection (10&#x02009;&#x000b5;l/g body weight of a 15&#x02009;mg/ml solution) followed by inhalation anesthesia (isoflurane) and IVIS bioluminescence imaging (&#x02009;~10&#x02009;min post-luciferin injection). Tumor burden was quantified using Living Image Software (v4.7.2, PerkinElmer). One mouse engrafted with 697<sup><italic>KI</italic></sup> treated with Vehicle was excluded due to imaging failure.</p><p id="Par82">For the in-vivo dosing experiments in Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9g</xref>, 0.25&#x02009;&#x000d7;&#x02009;10<sup>6</sup> 697<sup><italic>WT</italic></sup> cells were injected by tail vein injection into sub-lethally (2&#x02009;Gy) irradiated 11-13 week-old old male NSG mice. Mice received a daily dose of Venetoclax (100&#x02009;mg/kg) and/or Inobrodib (20&#x02009;mg/kg) or vehicle control (as above), by means of oral gavage until the experimental endpoints were reached.</p><p id="Par83">For the in-vivo dosing experiments in Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9h</xref>, the <italic>CREBBP</italic>-mutated male, pediatric patient presented was genomically and genetically characterized by the VIVO Biobank as having a high hyperdiploid karyotype alongside heterozygous CREBBP p.(Glu1551_Ser1552insArgArgPro) and NRAS p.(Gly12Cys) mutations. High quality primary diagnostic cells were obtained from the VIVO Biobank and engrafted by tail vein injection into sub-lethally irradiated NSG mice. For the dosing experiments, 1.2 million secondary PDX cells were engrafted into sub-lethally irradiated NSG mice. Recipients were 17-23 week-old old male and female NSG mice. Animals were randomized by sex and weight (Vehicle 2&#x02009;M/3&#x02009;F; Inobrodib 2&#x02009;M/3&#x02009;F; Venetoclax 2&#x02009;M/5&#x02009;F; Combination 3&#x02009;M/4&#x02009;F). Dosing was performed as above from day 77, except the schedule was 3 consecutive days per week for a maximum of 10 weeks. For the histology presented in Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9f</xref>, mice received two daily doses from D107 after transplantation.</p><p id="Par84">Mice were housed in a pathogen-free animal facility and were allowed unrestricted access to food and water, including irradiated complete universal diet for rats, mice and hamsters (SAFE R105-25), supplemented by DietGel 76&#x02009;A (Clear H<sub>2</sub>O 72-07-5022), NutraGel (BioServ NGB) and/or peanut butter provided across all groups during drug dosing. Housing and care of all animals included in this study were according to the UK&#x02019;s Home Office CoP with a 7am-7pm light/dark cycle (with a dawn/dusk cycle incorporated). Ambient temperature and relative humidity parameters were kept within 19&#x02013;23&#x02009;<sup>o</sup>C &#x00026; 45&#x02013;55%, respectively. Mice showing any clinical signs or weight loss (more than 20% of its reference weight post irradiation or 15% after administration of therapeutics), or sustained signs of compromised wellbeing such as reduced activity, piloerection and hunching that persisted for more than 6&#x02009;h (or 2 health checks separated by at least three hours) were humanely sacrificed. One mouse engrafted with 697<sup><italic>KI</italic></sup> treated with Vehicle was excluded from summary BLI measurements due to imaging failure. No other animals were excluded from analysis. The investigator was not blinded to the group allocation, however, the animal technicians who provided the majority of animal care and who decided upon which animals to sacrifice (according to defined endpoints) were blinded to the allocation.</p><p id="Par85">Sample sizes were based on pilot studies showing median survival times for 697 cells. For the Venetoclax dosing studies in Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9a&#x02013;f</xref>, a sample size of 6 was chosen to detect a 5&#x02009;&#x000b1;&#x02009;3 day OS benefit in the treatment arm, based on an alpha of 0.05 and a power of 80% and an anticipated engraftment time of 24 days in the control group. For the combination studies in Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9g</xref>, minimal control numbers were used for Venetoclax or vehicle dosing in line with three R principles. The number of mice used for treatment of either Inobrodib or Inobrodib with Venetoclax was calculated as four per arm, based on an anticipated survival benefit of 6&#x02009;&#x000b1;&#x02009;3 days in the dual treatment arm, based on an alpha of 0.05 and a power of 80% and an anticipated engraftment time of 24 days in the control group. For the combination dosing studies in PDX in Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9h</xref> a minimal sample size of 5 was chosen to detect a 35&#x02009;&#x000b1;&#x02009;20 day OS benefit in the treatment arms, based on an alpha of 0.05 and a power of 80% and a predicted latency of 120 days. Power calculations were calculated using ClinCalc.com.</p></sec><sec id="Sec33"><title>Histology</title><p id="Par86">Formalin fixed embedded splenic tissue was deparaffinized, rehydrated, antigen retrieved in citrate buffer (pH 6.0) and blocked with hydrogen peroxide. Washes were performed with TBS/Tween20 (0.05%). Primary antibodies (4HNE (Abcam, ab46545, Lot: 1073022-2), GPX4 (Abcam, ab41787, Lot: 1047829-4)) were diluted 1:200 in milk and detected by HRP-conjugate. Nuclei were stained with Harris&#x02019;s Haematoxylin counterstain. Images were obtained on a Zeiss Axioimager M2.</p></sec><sec id="Sec34"><title>Statistics</title><p id="Par87">Flow cytometric data was analyzed using FlowJo (v10). Statistical analysis was performed in GraphPad Prism-v9 and Microsoft Excel. Seahorse data was processed on Wave software (2.6.3). Significance tests are stated in figure legends</p></sec><sec id="Sec35"><title>Reporting summary</title><p id="Par88">Further information on research design is available in the&#x000a0;<xref rid="MOESM7" ref-type="media">Nature Portfolio Reporting Summary</xref> linked to this article.</p></sec></sec><sec id="Sec36" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41467_2025_59531_MOESM1_ESM.pdf"><caption><p>Supplementary Information</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41467_2025_59531_MOESM2_ESM.docx"><caption><p>Description of Additional Supplementary Information</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41467_2025_59531_MOESM3_ESM.xlsx"><caption><p>Supplementary Data 1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="41467_2025_59531_MOESM4_ESM.xlsx"><caption><p>Supplementary Data 2</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="41467_2025_59531_MOESM5_ESM.xlsx"><caption><p>Supplementary Data 3</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="41467_2025_59531_MOESM6_ESM.xlsx"><caption><p>Supplementary Data 4</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM7"><media xlink:href="41467_2025_59531_MOESM7_ESM.pdf"><caption><p>Reporting Summary</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM8"><media xlink:href="41467_2025_59531_MOESM8_ESM.pdf"><caption><p>Transparent Peer Review file</p></caption></media></supplementary-material>
</p></sec><sec id="Sec37" sec-type="supplementary-material"><title>Source data</title><p>
<supplementary-material content-type="local-data" id="MOESM9"><media xlink:href="41467_2025_59531_MOESM9_ESM.xlsx"><caption><p>Source Data</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>These authors jointly supervised this work: Brian J. P. Huntly, Simon E. Richardson.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41467-025-59531-6.</p></sec><ack><title>Acknowledgements</title><p>S.E.R. is supported by a Clinician Scientist Fellowship from Cancer Research UK (C67279/A27957), a Leukemia UK John Goldman Fellowship (2022/JGF/004), a European Hematology Association Physician Scientist Research Grant and funds from the Isaac Newton Trust. We would like to thank funders of the Huntly laboratory including Cancer Research UK (C18680/A25508, C355/A26819 and DRCRPG-Nov22/100014), the European Research Council (647685), MRC (MR-R009708-1 and MR-X008371) and the Kay Kendall Leukemia Fund (KKL1243 and KKL1440). B.J.P.H. is part of a Strategic Center of Research (7035-24) supported by The Leukemia &#x00026; Lymphoma Society and Blood Cancer UK. This research was supported by the NIHR Cambridge Biomedical Research Center (BRC-1215-20014) and the Cancer Research UK Cambridge Center (Cancer Research UK Major Center Award C9685/A25117), and was funded in part by the Wellcome Trust, who supported the Cambridge Stem Cell Institute (203151/Z/16/Z and 226795/Z/22/Z) and Cambridge Institute for Medical Research (100140/Z/12/Z). N.N. was funded by a Kay Kendall Leukemia Fund Junior Fellowship (KKL1440). J.B. was funded by the Wellcome Trust 4-Year MRes+PhD Program in Stem Cell Biology and Medicine (218481/Z/19/Z). T.B. was funded by a Clinical Research Training Fellowship from the Cancer Research UK Cambridge Center Clinical Academic Training Program (SEBSTF-2021\100001). M.R.M. is funded by a GOSHCC professorship. K.F. is jointly funded by CRUK and Children with Cancer charity (grant number DRCPGM\100066). Work in the MPM lab was supported by the Medical Research Council UK (MC_UU_00028/4). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. For the purpose of Open Access, the author has applied for a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. We acknowledge support from the Cancer Research UK Cambridge Center Genomics and Proteomics Facilities, the Cambridge Institute for Medical Research Flow Cytometry Facility, the NIHR Cambridge BRC Cell Phenotyping Hub and the CSCI histology and imaging facilities. We thank Thomas Mercher and Johannes Zuber for use of the pLT3GEPIR inducible shRNA system. We thank Atsushi Miyawaki at the RIKEN BioResource Research Center for the use of the FUCCI cell cycle reporter system. We thank Anthony Moorman for his assistance in identification of <italic>CREBBP</italic>-mutated patient samples. Patient samples used in this study were provided by VIVO Biobank, supported by Cancer Research UK &#x00026; Blood Cancer UK (Grant no. CRCPSC-Dec21\100003).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>A.G.-G., J.E.D., D.M.A.A., G.G., R.A., E.M., J.B., N.S., C.K.L., N.N., T.B., S.A.S., K.F., H.B.R.A., B.J., A.K., S.J.H. and S.E.R. performed the experiments and analyzed the data. A.G.-G., G.G., D.O.C., M.R.M., H.B.R.A., A.K., M.P.M., S.J.H., B.J.P.H. and S.E.R. wrote, reviewed and edited the manuscript. B.J.H.P. and S.E.R. conceptualized the study, acquired funding and supervised the project.</p></notes><notes notes-type="peer-review"><title>Peer review</title><sec id="FPar1"><title>Peer review information</title><p id="Par89"><italic>Nature Communications</italic> thanks Barrie Peck, Isidro Sanchez-Garcia, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available.</p></sec></notes><notes notes-type="data-availability"><title>Data availability</title><p>Raw sequencing data for RNAseq, ChIPseq and CUR&#x00026;RUN are deposited in GEO Archive under accession numbers GSE248265, GSE289011 and GSE289012 respectively [<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/">https://www.ncbi.nlm.nih.gov/geo/</ext-link>]. The total proteomics data generated in this study have been deposited in the ProteomeXchange database under accession code PXD061362 [<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/pride/archive?sortDirection=DESC&#x00026;page=0&#x00026;pageSize=20">https://www.ebi.ac.uk/pride/archive?sortDirection=DESC&#x00026;page=0&#x00026;pageSize=20</ext-link>]. The total lipidomics data generated in this study have been deposited in the MassIVE database under accession code MSV000097461 [<ext-link ext-link-type="uri" xlink:href="https://massive.ucsd.edu/ProteoSAFe/dataset.jsp?task=6746d9c3cb2d4c4e957cde41bd03aa08">https://massive.ucsd.edu/ProteoSAFe/dataset.jsp?task=6746d9c3cb2d4c4e957cde41bd03aa08</ext-link>]. Further information and requests for resources and reagents should be directed to and will be fulfilled by the corresponding author.&#x000a0;<xref ref-type="sec" rid="Sec37">Source data</xref> are provided with this paper.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par90">N.N. is a former employee of the Walter and Eliza Hall Institute which receives milestone and royalty payments related to Venetoclax. N.N. received payments from WEHI related to Venetoclax. The combination of BCL2 and CREBBP/EP300 inhibitors in ALL is protected under Cambridge Enterprise patent PCT/GB2024/052398 (S.E.R. and B.P.J.H. listed inventors). The remaining authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Hunger</surname><given-names>SP</given-names></name><name><surname>Mullighan</surname><given-names>CG</given-names></name></person-group><article-title>Acute lymphoblastic leukemia in children</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>373</volume><fpage>1541</fpage><lpage>1552</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1400972</pub-id><pub-id pub-id-type="pmid">26465987</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Hunger, S. P. &#x00026; Mullighan, C. G. Acute lymphoblastic leukemia in children. <italic>N. Engl. J. Med.</italic><bold>373</bold>, 1541&#x02013;1552 (2015).<pub-id pub-id-type="pmid">26465987</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Pasqualucci</surname><given-names>L</given-names></name><etal/></person-group><article-title>Inactivating mutations of acetyltransferase genes in B-cell lymphoma</article-title><source>Nature</source><year>2011</year><volume>471</volume><fpage>189</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1038/nature09730</pub-id><pub-id pub-id-type="pmid">21390126</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Pasqualucci, L. et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. <italic>Nature</italic><bold>471</bold>, 189&#x02013;195 (2011).<pub-id pub-id-type="pmid">21390126</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Horton</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors</article-title><source>Nat. Cell Biol.</source><year>2017</year><volume>19</volume><fpage>1093</fpage><lpage>1104</lpage><pub-id pub-id-type="doi">10.1038/ncb3597</pub-id><pub-id pub-id-type="pmid">28825697</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Horton, S. J. et al. Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. <italic>Nat. Cell Biol.</italic><bold>19</bold>, 1093&#x02013;1104 (2017).<pub-id pub-id-type="pmid">28825697</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Mullighan</surname><given-names>CG</given-names></name><etal/></person-group><article-title>CREBBP mutations in relapsed acute lymphoblastic leukaemia</article-title><source>Nature</source><year>2011</year><volume>471</volume><fpage>235</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1038/nature09727</pub-id><pub-id pub-id-type="pmid">21390130</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Mullighan, C. G. et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. <italic>Nature</italic><bold>471</bold>, 235&#x02013;239 (2011).<pub-id pub-id-type="pmid">21390130</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Brady</surname><given-names>SW</given-names></name><etal/></person-group><article-title>The genomic landscape of pediatric acute lymphoblastic leukemia</article-title><source>Nat. Genet</source><year>2022</year><volume>54</volume><fpage>1376</fpage><lpage>1389</lpage><pub-id pub-id-type="doi">10.1038/s41588-022-01159-z</pub-id><pub-id pub-id-type="pmid">36050548</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Brady, S. W. et al. The genomic landscape of pediatric acute lymphoblastic leukemia. <italic>Nat. Genet</italic><bold>54</bold>, 1376&#x02013;1389 (2022).<pub-id pub-id-type="pmid">36050548</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Holmfeldt</surname><given-names>L</given-names></name><etal/></person-group><article-title>The genomic landscape of hypodiploid acute lymphoblastic leukemia</article-title><source>Nat. Genet</source><year>2013</year><volume>45</volume><fpage>242</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1038/ng.2532</pub-id><pub-id pub-id-type="pmid">23334668</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Holmfeldt, L. et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. <italic>Nat. Genet</italic><bold>45</bold>, 242&#x02013;252 (2013).<pub-id pub-id-type="pmid">23334668</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Inthal</surname><given-names>A</given-names></name><etal/></person-group><article-title>CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia</article-title><source>Leukemia</source><year>2012</year><volume>26</volume><fpage>1797</fpage><lpage>1803</lpage><pub-id pub-id-type="doi">10.1038/leu.2012.60</pub-id><pub-id pub-id-type="pmid">22388726</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Inthal, A. et al. CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia. <italic>Leukemia</italic><bold>26</bold>, 1797&#x02013;1803 (2012).<pub-id pub-id-type="pmid">22388726</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><etal/></person-group><article-title>Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia</article-title><source>Blood</source><year>2020</year><volume>135</volume><fpage>41</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1182/blood.2019002220</pub-id><pub-id pub-id-type="pmid">31697823</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Li, B. et al. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. <italic>Blood</italic><bold>135</bold>, 41&#x02013;55 (2020).<pub-id pub-id-type="pmid">31697823</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Waanders</surname><given-names>E</given-names></name><etal/></person-group><article-title>Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia</article-title><source>Blood Cancer Discov.</source><year>2020</year><volume>1</volume><fpage>96</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.BCD-19-0041</pub-id><pub-id pub-id-type="pmid">32793890</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Waanders, E. et al. Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia. <italic>Blood Cancer Discov.</italic><bold>1</bold>, 96&#x02013;111 (2020).<pub-id pub-id-type="pmid">32793890</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>C</given-names></name><etal/></person-group><article-title>Downregulating CREBBP inhibits proliferation and cell cycle progression and induces daunorubicin resistance in leukemia cells</article-title><source>Mol. Med Rep.</source><year>2020</year><volume>22</volume><fpage>2905</fpage><lpage>2915</lpage><pub-id pub-id-type="pmid">32945392</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Gao, C. et al. Downregulating CREBBP inhibits proliferation and cell cycle progression and induces daunorubicin resistance in leukemia cells. <italic>Mol. Med Rep.</italic><bold>22</bold>, 2905&#x02013;2915 (2020).<pub-id pub-id-type="pmid">32945392</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Chougule</surname><given-names>RA</given-names></name><name><surname>Shah</surname><given-names>K</given-names></name><name><surname>Moharram</surname><given-names>SA</given-names></name><name><surname>Vallon-Christersson</surname><given-names>J</given-names></name><name><surname>Kazi</surname><given-names>JU</given-names></name></person-group><article-title>Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation</article-title><source>NPJ Genom. Med</source><year>2019</year><volume>4</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1038/s41525-019-0082-y</pub-id><pub-id pub-id-type="pmid">30962949</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Chougule, R. A., Shah, K., Moharram, S. A., Vallon-Christersson, J. &#x00026; Kazi, J. U. Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation. <italic>NPJ Genom. Med</italic><bold>4</bold>, 7 (2019).<pub-id pub-id-type="pmid">30962949</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>ZA</given-names></name><etal/></person-group><article-title>CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response</article-title><source>Haematologica</source><year>2017</year><volume>102</volume><fpage>736</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.3324/haematol.2016.145177</pub-id><pub-id pub-id-type="pmid">27979926</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Dixon, Z. A. et al. CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response. <italic>Haematologica</italic><bold>102</bold>, 736&#x02013;745 (2017).<pub-id pub-id-type="pmid">27979926</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Lamble</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>CREBBP alterations are associated with a poor prognosis in de novo AML</article-title><source>Blood</source><year>2023</year><volume>141</volume><fpage>2156</fpage><lpage>2159</lpage><pub-id pub-id-type="pmid">36634304</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Lamble, A. J. et al. CREBBP alterations are associated with a poor prognosis in de novo AML. <italic>Blood</italic><bold>141</bold>, 2156&#x02013;2159 (2023).<pub-id pub-id-type="pmid">36634304</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>An easy-to-use nomogram predicting overall survival of adult acute lymphoblastic leukemia</article-title><source>Front Oncol.</source><year>2022</year><volume>12</volume><fpage>977119</fpage><pub-id pub-id-type="doi">10.3389/fonc.2022.977119</pub-id><pub-id pub-id-type="pmid">36226057</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Liu, Y. et al. An easy-to-use nomogram predicting overall survival of adult acute lymphoblastic leukemia. <italic>Front Oncol.</italic><bold>12</bold>, 977119 (2022).<pub-id pub-id-type="pmid">36226057</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016</article-title><source>Blood</source><year>2019</year><volume>133</volume><fpage>81</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-07-865428</pub-id><pub-id pub-id-type="pmid">30446494</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Qu, X. et al. Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016. <italic>Blood</italic><bold>133</bold>, 81&#x02013;93 (2019).<pub-id pub-id-type="pmid">30446494</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Balducci</surname><given-names>E</given-names></name><etal/></person-group><article-title>Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL</article-title><source>Blood</source><year>2024</year><volume>144</volume><fpage>988</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1182/blood.2023022154</pub-id><pub-id pub-id-type="pmid">38518104</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Balducci, E. et al. Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL. <italic>Blood</italic><bold>144</bold>, 988&#x02013;1000 (2024).<pub-id pub-id-type="pmid">38518104</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Malinowska-Ozdowy</surname><given-names>K</given-names></name><etal/></person-group><article-title>KRAS and CREBBP mutations: A relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia</article-title><source>Leukemia</source><year>2015</year><volume>29</volume><fpage>1656</fpage><lpage>1667</lpage><pub-id pub-id-type="doi">10.1038/leu.2015.107</pub-id><pub-id pub-id-type="pmid">25917266</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Malinowska-Ozdowy, K. et al. KRAS and CREBBP mutations: A relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia. <italic>Leukemia</italic><bold>29</bold>, 1656&#x02013;1667 (2015).<pub-id pub-id-type="pmid">25917266</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>SN</given-names></name><etal/></person-group><article-title>Unique and shared epigenetic programs of the CREBBP and EP300 acetyltransferases in germinal center B cells reveal targetable dependencies in lymphoma</article-title><source>Immunity</source><year>2019</year><volume>51</volume><fpage>535</fpage><lpage>547.e539</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.08.006</pub-id><pub-id pub-id-type="pmid">31519498</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Meyer, S. N. et al. Unique and shared epigenetic programs of the CREBBP and EP300 acetyltransferases in germinal center B cells reveal targetable dependencies in lymphoma. <italic>Immunity</italic><bold>51</bold>, 535&#x02013;547.e539 (2019).<pub-id pub-id-type="pmid">31519498</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Lord, C. J., Quinn, N. &#x00026; Ryan, C. J. Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactions. <italic>Elife</italic><bold>9</bold>10.7554/eLife.58925 (2020).</mixed-citation></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Dutto</surname><given-names>I</given-names></name><name><surname>Scalera</surname><given-names>C</given-names></name><name><surname>Prosperi</surname><given-names>E</given-names></name></person-group><article-title>CREBBP and p300 lysine acetyl transferases in the DNA damage response</article-title><source>Cell Mol. Life Sci.</source><year>2018</year><volume>75</volume><fpage>1325</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1007/s00018-017-2717-4</pub-id><pub-id pub-id-type="pmid">29170789</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Dutto, I., Scalera, C. &#x00026; Prosperi, E. CREBBP and p300 lysine acetyl transferases in the DNA damage response. <italic>Cell Mol. Life Sci.</italic><bold>75</bold>, 1325&#x02013;1338 (2018).<pub-id pub-id-type="pmid">29170789</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Irving</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia</article-title><source>Blood</source><year>2016</year><volume>128</volume><fpage>911</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-03-704973</pub-id><pub-id pub-id-type="pmid">27229005</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Irving, J. A. et al. Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. <italic>Blood</italic><bold>128</bold>, 911&#x02013;922 (2016).<pub-id pub-id-type="pmid">27229005</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz-Flores</surname><given-names>E</given-names></name><etal/></person-group><article-title>Bcl-2 is a therapeutic target for hypodiploid B-lineage acute lymphoblastic leukemia</article-title><source>Cancer Res</source><year>2019</year><volume>79</volume><fpage>2339</fpage><lpage>2351</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-0236</pub-id><pub-id pub-id-type="pmid">30862722</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Diaz-Flores, E. et al. Bcl-2 is a therapeutic target for hypodiploid B-lineage acute lymphoblastic leukemia. <italic>Cancer Res</italic><bold>79</bold>, 2339&#x02013;2351 (2019).<pub-id pub-id-type="pmid">30862722</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Roca-Portoles</surname><given-names>A</given-names></name><etal/></person-group><article-title>Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition</article-title><source>Cell Death Dis.</source><year>2020</year><volume>11</volume><fpage>616</fpage><pub-id pub-id-type="doi">10.1038/s41419-020-02867-2</pub-id><pub-id pub-id-type="pmid">32792521</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Roca-Portoles, A. et al. Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition. <italic>Cell Death Dis.</italic><bold>11</bold>, 616 (2020).<pub-id pub-id-type="pmid">32792521</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Pollyea</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia</article-title><source>Nat. Med</source><year>2018</year><volume>24</volume><fpage>1859</fpage><lpage>1866</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0233-1</pub-id><pub-id pub-id-type="pmid">30420752</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Pollyea, D. A. et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. <italic>Nat. Med</italic><bold>24</bold>, 1859&#x02013;1866 (2018).<pub-id pub-id-type="pmid">30420752</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Lagadinou</surname><given-names>ED</given-names></name><etal/></person-group><article-title>BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells</article-title><source>Cell Stem Cell</source><year>2013</year><volume>12</volume><fpage>329</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2012.12.013</pub-id><pub-id pub-id-type="pmid">23333149</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Lagadinou, E. D. et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. <italic>Cell Stem Cell</italic><bold>12</bold>, 329&#x02013;341 (2013).<pub-id pub-id-type="pmid">23333149</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Fellmann</surname><given-names>C</given-names></name><etal/></person-group><article-title>An optimized microRNA backbone for effective single-copy RNAi</article-title><source>Cell Rep.</source><year>2013</year><volume>5</volume><fpage>1704</fpage><lpage>1713</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2013.11.020</pub-id><pub-id pub-id-type="pmid">24332856</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Fellmann, C. et al. An optimized microRNA backbone for effective single-copy RNAi. <italic>Cell Rep.</italic><bold>5</bold>, 1704&#x02013;1713 (2013).<pub-id pub-id-type="pmid">24332856</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B-cell lymphoma</article-title><source>Cancer Discov.</source><year>2017</year><volume>7</volume><fpage>322</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-16-1417</pub-id><pub-id pub-id-type="pmid">28069569</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Zhang, J. et al. The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B-cell lymphoma. <italic>Cancer Discov.</italic><bold>7</bold>, 322&#x02013;337 (2017).<pub-id pub-id-type="pmid">28069569</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Target analysis by integration of transcriptome and ChIP-seq data with BETA</article-title><source>Nat. Protoc.</source><year>2013</year><volume>8</volume><fpage>2502</fpage><lpage>2515</lpage><pub-id pub-id-type="doi">10.1038/nprot.2013.150</pub-id><pub-id pub-id-type="pmid">24263090</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Wang, S. et al. Target analysis by integration of transcriptome and ChIP-seq data with BETA. <italic>Nat. Protoc.</italic><bold>8</bold>, 2502&#x02013;2515 (2013).<pub-id pub-id-type="pmid">24263090</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Ferroptosis: An iron-dependent form of nonapoptotic cell death</article-title><source>Cell</source><year>2012</year><volume>149</volume><fpage>1060</fpage><lpage>1072</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.03.042</pub-id><pub-id pub-id-type="pmid">22632970</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Dixon, S. J. et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. <italic>Cell</italic><bold>149</bold>, 1060&#x02013;1072 (2012).<pub-id pub-id-type="pmid">22632970</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><etal/></person-group><article-title>Human hematopoietic stem cell vulnerability to ferroptosis</article-title><source>Cell</source><year>2023</year><volume>186</volume><fpage>732</fpage><lpage>747.e716</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2023.01.020</pub-id><pub-id pub-id-type="pmid">36803603</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Zhao, J. et al. Human hematopoietic stem cell vulnerability to ferroptosis. <italic>Cell</italic><bold>186</bold>, 732&#x02013;747.e716 (2023).<pub-id pub-id-type="pmid">36803603</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Huo</surname><given-names>H</given-names></name><etal/></person-group><article-title>Erastin disrupts mitochondrial permeability transition pore (mPTP) and induces apoptotic death of colorectal cancer cells</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><fpage>e0154605</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0154605</pub-id><pub-id pub-id-type="pmid">27171435</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Huo, H. et al. Erastin disrupts mitochondrial permeability transition pore (mPTP) and induces apoptotic death of colorectal cancer cells. <italic>PLoS One</italic><bold>11</bold>, e0154605 (2016).<pub-id pub-id-type="pmid">27171435</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Yagoda</surname><given-names>N</given-names></name><etal/></person-group><article-title>RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels</article-title><source>Nature</source><year>2007</year><volume>447</volume><fpage>864</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1038/nature05859</pub-id><pub-id pub-id-type="pmid">17568748</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Yagoda, N. et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. <italic>Nature</italic><bold>447</bold>, 864&#x02013;868 (2007).<pub-id pub-id-type="pmid">17568748</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Lalonde</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Genome-wide CRISPR screens identify ferroptosis as a novel therapeutic vulnerability in acute lymphoblastic leukemia</article-title><source>Haematologica</source><year>2023</year><volume>108</volume><fpage>382</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.3324/haematol.2022.280786</pub-id><pub-id pub-id-type="pmid">36134452</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Lalonde, M. E. et al. Genome-wide CRISPR screens identify ferroptosis as a novel therapeutic vulnerability in acute lymphoblastic leukemia. <italic>Haematologica</italic><bold>108</bold>, 382&#x02013;393 (2023).<pub-id pub-id-type="pmid">36134452</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Udagawa</surname><given-names>J</given-names></name><name><surname>Hino</surname><given-names>K</given-names></name></person-group><article-title>Plasmalogen in the brain: Effects on cognitive functions and behaviors attributable to its properties</article-title><source>Brain Res. Bull.</source><year>2022</year><volume>188</volume><fpage>197</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/j.brainresbull.2022.08.008</pub-id><pub-id pub-id-type="pmid">35970332</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Udagawa, J. &#x00026; Hino, K. Plasmalogen in the brain: Effects on cognitive functions and behaviors attributable to its properties. <italic>Brain Res. Bull.</italic><bold>188</bold>, 197&#x02013;202 (2022).<pub-id pub-id-type="pmid">35970332</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Ether phospholipids are required for mitochondrial reactive oxygen species homeostasis</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>2194</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-37924-9</pub-id><pub-id pub-id-type="pmid">37069167</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Chen, Z. et al. Ether phospholipids are required for mitochondrial reactive oxygen species homeostasis. <italic>Nat. Commun.</italic><bold>14</bold>, 2194 (2023).<pub-id pub-id-type="pmid">37069167</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name><name><surname>Chu</surname><given-names>B</given-names></name></person-group><article-title>Peroxisome-driven ether-linked phospholipids biosynthesis is essential for ferroptosis</article-title><source>Cell Death Differ.</source><year>2021</year><volume>28</volume><fpage>2536</fpage><lpage>2551</lpage><pub-id pub-id-type="doi">10.1038/s41418-021-00769-0</pub-id><pub-id pub-id-type="pmid">33731874</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Cui, W., Liu, D., Gu, W. &#x00026; Chu, B. Peroxisome-driven ether-linked phospholipids biosynthesis is essential for ferroptosis. <italic>Cell Death Differ.</italic><bold>28</bold>, 2536&#x02013;2551 (2021).<pub-id pub-id-type="pmid">33731874</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Perez</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Ether lipid deficiency disrupts lipid homeostasis leading to ferroptosis sensitivity</article-title><source>PLoS Genet</source><year>2022</year><volume>18</volume><fpage>e1010436</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1010436</pub-id><pub-id pub-id-type="pmid">36178986</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Perez, M. A. et al. Ether lipid deficiency disrupts lipid homeostasis leading to ferroptosis sensitivity. <italic>PLoS Genet</italic><bold>18</bold>, e1010436 (2022).<pub-id pub-id-type="pmid">36178986</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>KG</given-names></name><etal/></person-group><article-title>Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia</article-title><source>N. Engl. J. Med</source><year>2014</year><volume>371</volume><fpage>1005</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1403088</pub-id><pub-id pub-id-type="pmid">25207766</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Roberts, K. G. et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. <italic>N. Engl. J. Med</italic>. <bold>371</bold>, 1005&#x02013;1015 (2014).<pub-id pub-id-type="pmid">25207766</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Plasticity of ether lipids promotes ferroptosis susceptibility and evasion</article-title><source>Nature</source><year>2020</year><volume>585</volume><fpage>603</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2732-8</pub-id><pub-id pub-id-type="pmid">32939090</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Zou, Y. et al. Plasticity of ether lipids promotes ferroptosis susceptibility and evasion. <italic>Nature</italic><bold>585</bold>, 603&#x02013;608 (2020).<pub-id pub-id-type="pmid">32939090</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Herling</surname><given-names>CD</given-names></name><etal/></person-group><article-title>Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>727</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-03170-7</pub-id><pub-id pub-id-type="pmid">29463802</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Herling, C. D. et al. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. <italic>Nat. Commun.</italic><bold>9</bold>, 727 (2018).<pub-id pub-id-type="pmid">29463802</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Shoshan-Barmatz, V., Shteinfer-Kuzmine, A. &#x00026; Verma, A. VDAC1 at the intersection of cell metabolism, apoptosis, and diseases. <italic>Biomolecules</italic><bold>10</bold>10.3390/biom10111485 (2020).</mixed-citation></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Maldonado</surname><given-names>EN</given-names></name><etal/></person-group><article-title>Voltage-dependent anion channels modulate mitochondrial metabolism in cancer cells: Regulation by free tubulin and erastin</article-title><source>J. Biol. Chem.</source><year>2013</year><volume>288</volume><fpage>11920</fpage><lpage>11929</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.433847</pub-id><pub-id pub-id-type="pmid">23471966</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Maldonado, E. N. et al. Voltage-dependent anion channels modulate mitochondrial metabolism in cancer cells: Regulation by free tubulin and erastin. <italic>J. Biol. Chem.</italic><bold>288</bold>, 11920&#x02013;11929 (2013).<pub-id pub-id-type="pmid">23471966</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="other">Place, A. E. et al. Pediatric patients with relapsed/refractory acute lymphoblastic leukemia harboring heterogeneous genomic profiles respond to venetoclax in combination with chemotherapy. <italic>Blood</italic><bold>136</bold>10.1182/blood-2020-137376 (2020).</mixed-citation></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>SJ</given-names></name><name><surname>Pratt</surname><given-names>DA</given-names></name></person-group><article-title>Ferroptosis: A flexible constellation of related biochemical mechanisms</article-title><source>Mol. Cell</source><year>2023</year><volume>83</volume><fpage>1030</fpage><lpage>1042</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2023.03.005</pub-id><pub-id pub-id-type="pmid">36977413</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Dixon, S. J. &#x00026; Pratt, D. A. Ferroptosis: A flexible constellation of related biochemical mechanisms. <italic>Mol. Cell</italic><bold>83</bold>, 1030&#x02013;1042 (2023).<pub-id pub-id-type="pmid">36977413</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Borzillo</surname><given-names>GV</given-names></name><name><surname>Ashmun</surname><given-names>RA</given-names></name><name><surname>Sherr</surname><given-names>CJ</given-names></name></person-group><article-title>Macrophage lineage switching of murine early pre-B lymphoid cells expressing transduced fms genes</article-title><source>Mol. Cell Biol.</source><year>1990</year><volume>10</volume><fpage>2703</fpage><lpage>2714</lpage><pub-id pub-id-type="pmid">2160584</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Borzillo, G. V., Ashmun, R. A. &#x00026; Sherr, C. J. Macrophage lineage switching of murine early pre-B lymphoid cells expressing transduced fms genes. <italic>Mol. Cell Biol.</italic><bold>10</bold>, 2703&#x02013;2714 (1990).<pub-id pub-id-type="pmid">2160584</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Blobel</surname><given-names>GA</given-names></name></person-group><article-title>CREB-binding protein and p300: Molecular integrators of hematopoietic transcription</article-title><source>Blood</source><year>2000</year><volume>95</volume><fpage>745</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1182/blood.V95.3.745.003k05_745_755</pub-id><pub-id pub-id-type="pmid">10648382</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Blobel, G. A. CREB-binding protein and p300: Molecular integrators of hematopoietic transcription. <italic>Blood</italic><bold>95</bold>, 745&#x02013;755 (2000).<pub-id pub-id-type="pmid">10648382</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Honsho</surname><given-names>M</given-names></name><name><surname>Asaoku</surname><given-names>S</given-names></name><name><surname>Fujiki</surname><given-names>Y</given-names></name></person-group><article-title>Posttranslational regulation of fatty acyl-CoA reductase 1, Far1, controls ether glycerophospholipid synthesis</article-title><source>J. Biol. Chem.</source><year>2010</year><volume>285</volume><fpage>8537</fpage><lpage>8542</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.083311</pub-id><pub-id pub-id-type="pmid">20071337</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Honsho, M., Asaoku, S. &#x00026; Fujiki, Y. Posttranslational regulation of fatty acyl-CoA reductase 1, Far1, controls ether glycerophospholipid synthesis. <italic>J. Biol. Chem.</italic><bold>285</bold>, 8537&#x02013;8542 (2010).<pub-id pub-id-type="pmid">20071337</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Biermann</surname><given-names>J</given-names></name><name><surname>Just</surname><given-names>WW</given-names></name><name><surname>Wanders</surname><given-names>RJ</given-names></name><name><surname>Van Den Bosch</surname><given-names>H</given-names></name></person-group><article-title>Alkyl-dihydroxyacetone phosphate synthase and dihydroxyacetone phosphate acyltransferase form a protein complex in peroxisomes</article-title><source>Eur. J. Biochem</source><year>1999</year><volume>261</volume><fpage>492</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1046/j.1432-1327.1999.00295.x</pub-id><pub-id pub-id-type="pmid">10215861</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Biermann, J., Just, W. W., Wanders, R. J. &#x00026; Van Den Bosch, H. Alkyl-dihydroxyacetone phosphate synthase and dihydroxyacetone phosphate acyltransferase form a protein complex in peroxisomes. <italic>Eur. J. Biochem</italic><bold>261</bold>, 492&#x02013;499 (1999).<pub-id pub-id-type="pmid">10215861</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">Brooks, N. et al. CCS1477, a novel p300/CBP bromodomain inhibitor, enhances efficacy of azacitidine and venetoclax in pre-clinical models of acute myeloid leukaemia and lymphoma. <italic>Blood</italic><bold>138</bold>10.1182/blood-2021-148295 (2021).</mixed-citation></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Nicosia</surname><given-names>L</given-names></name><etal/></person-group><article-title>Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies</article-title><source>Cancer Cell</source><year>2023</year><volume>41</volume><fpage>2136</fpage><lpage>2153.e2113</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2023.11.001</pub-id><pub-id pub-id-type="pmid">37995682</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Nicosia, L. et al. Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. <italic>Cancer Cell</italic><bold>41</bold>, 2136&#x02013;2153.e2113 (2023).<pub-id pub-id-type="pmid">37995682</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>S</given-names></name><etal/></person-group><article-title>SynergyFinder Plus: Toward better interpretation and annotation of drug combination screening datasets</article-title><source>Genomics Proteom. Bioinforma.</source><year>2022</year><volume>20</volume><fpage>587</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1016/j.gpb.2022.01.004</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Zheng, S. et al. SynergyFinder Plus: Toward better interpretation and annotation of drug combination screening datasets. <italic>Genomics Proteom. Bioinforma.</italic><bold>20</bold>, 587&#x02013;596 (2022).</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Sakaue-Sawano</surname><given-names>A</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Ohtawa</surname><given-names>K</given-names></name><name><surname>Miyawaki</surname><given-names>A</given-names></name></person-group><article-title>Drug-induced cell cycle modulation leading to cell-cycle arrest, nuclear mis-segregation, or endoreplication</article-title><source>BMC Cell Biol.</source><year>2011</year><volume>12</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.1186/1471-2121-12-2</pub-id><pub-id pub-id-type="pmid">21226962</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Sakaue-Sawano, A., Kobayashi, T., Ohtawa, K. &#x00026; Miyawaki, A. Drug-induced cell cycle modulation leading to cell-cycle arrest, nuclear mis-segregation, or endoreplication. <italic>BMC Cell Biol.</italic><bold>12</bold>, 2 (2011).<pub-id pub-id-type="pmid">21226962</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Sakaue-Sawano</surname><given-names>A</given-names></name><etal/></person-group><article-title>Tracing the silhouette of individual cells in S/G2/M phases with fluorescence</article-title><source>Chem. Biol.</source><year>2008</year><volume>15</volume><fpage>1243</fpage><lpage>1248</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2008.10.015</pub-id><pub-id pub-id-type="pmid">19101468</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Sakaue-Sawano, A. et al. Tracing the silhouette of individual cells in S/G2/M phases with fluorescence. <italic>Chem. Biol.</italic><bold>15</bold>, 1243&#x02013;1248 (2008).<pub-id pub-id-type="pmid">19101468</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><mixed-citation publication-type="other">Jenkins, B., Ronis, M. &#x00026; Koulman, A. LC-MS Lipidomics: Exploiting a simple high-throughput method for the comprehensive extraction of lipids in a ruminant fat dose-response study. <italic>Metabolites</italic><bold>10</bold>10.3390/metabo10070296 (2020).</mixed-citation></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsugawa</surname><given-names>H</given-names></name><etal/></person-group><article-title>A lipidome atlas in MS-DIAL 4</article-title><source>Nat. Biotechnol.</source><year>2020</year><volume>38</volume><fpage>1159</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1038/s41587-020-0531-2</pub-id><pub-id pub-id-type="pmid">32541957</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Tsugawa, H. et al. A lipidome atlas in MS-DIAL 4. <italic>Nat. Biotechnol.</italic><bold>38</bold>, 1159&#x02013;1163 (2020).<pub-id pub-id-type="pmid">32541957</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Pellegrino</surname><given-names>RM</given-names></name><etal/></person-group><article-title>LipidOne: User-friendly lipidomic data analysis tool for a deeper interpretation in a systems biology scenario</article-title><source>Bioinformatics</source><year>2022</year><volume>38</volume><fpage>1767</fpage><lpage>1769</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btab867</pub-id><pub-id pub-id-type="pmid">34971364</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Pellegrino, R. M. et al. LipidOne: User-friendly lipidomic data analysis tool for a deeper interpretation in a systems biology scenario. <italic>Bioinformatics</italic><bold>38</bold>, 1767&#x02013;1769 (2022).<pub-id pub-id-type="pmid">34971364</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Alabed</surname><given-names>HBR</given-names></name><etal/></person-group><article-title>LipidOne 2.0: A web tool for discovering biological meanings hidden in lipidomic data</article-title><source>Curr. Protoc.</source><year>2024</year><volume>4</volume><fpage>e70009</fpage><pub-id pub-id-type="doi">10.1002/cpz1.70009</pub-id><pub-id pub-id-type="pmid">39301800</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Alabed, H. B. R. et al. LipidOne 2.0: A web tool for discovering biological meanings hidden in lipidomic data. <italic>Curr. Protoc.</italic><bold>4</bold>, e70009 (2024).<pub-id pub-id-type="pmid">39301800</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><etal/></person-group><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><year>2013</year><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. <italic>Bioinformatics</italic><bold>29</bold>, 15&#x02013;21 (2013).<pub-id pub-id-type="pmid">23104886</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name></person-group><article-title>featureCounts: An efficient general purpose program for assigning sequence reads to genomic features</article-title><source>Bioinformatics</source><year>2014</year><volume>30</volume><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt656</pub-id><pub-id pub-id-type="pmid">24227677</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Liao, Y., Smyth, G. K. &#x00026; Shi, W. featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. <italic>Bioinformatics</italic><bold>30</bold>, 923&#x02013;930 (2014).<pub-id pub-id-type="pmid">24227677</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biol.</source><year>2014</year><volume>15</volume><fpage>550</fpage><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Love, M. I., Huber, W. &#x00026; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. <italic>Genome Biol.</italic><bold>15</bold>, 550 (2014).<pub-id pub-id-type="pmid">25516281</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>LG</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>QY</given-names></name></person-group><article-title>clusterProfiler: An R package for comparing biological themes among gene clusters</article-title><source>OMICS</source><year>2012</year><volume>16</volume><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id><pub-id pub-id-type="pmid">22455463</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Yu, G., Wang, L. G., Han, Y. &#x00026; He, Q. Y. clusterProfiler: An R package for comparing biological themes among gene clusters. <italic>OMICS</italic><bold>16</bold>, 284&#x02013;287 (2012).<pub-id pub-id-type="pmid">22455463</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Bolger</surname><given-names>AM</given-names></name><name><surname>Lohse</surname><given-names>M</given-names></name><name><surname>Usadel</surname><given-names>B</given-names></name></person-group><article-title>Trimmomatic: A flexible trimmer for Illumina sequence data</article-title><source>Bioinformatics</source><year>2014</year><volume>30</volume><fpage>2114</fpage><lpage>2120</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu170</pub-id><pub-id pub-id-type="pmid">24695404</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Bolger, A. M., Lohse, M. &#x00026; Usadel, B. Trimmomatic: A flexible trimmer for Illumina sequence data. <italic>Bioinformatics</italic><bold>30</bold>, 2114&#x02013;2120 (2014).<pub-id pub-id-type="pmid">24695404</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Langmead</surname><given-names>B</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><article-title>Fast gapped-read alignment with Bowtie 2</article-title><source>Nat. Methods</source><year>2012</year><volume>9</volume><fpage>357</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1923</pub-id><pub-id pub-id-type="pmid">22388286</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Langmead, B. &#x00026; Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. <italic>Nat. Methods</italic><bold>9</bold>, 357&#x02013;359 (2012).<pub-id pub-id-type="pmid">22388286</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>The sequence alignment/map format and SAMtools</article-title><source>Bioinformatics</source><year>2009</year><volume>25</volume><fpage>2078</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp352</pub-id><pub-id pub-id-type="pmid">19505943</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Li, H. et al. The sequence alignment/map format and SAMtools. <italic>Bioinformatics</italic><bold>25</bold>, 2078&#x02013;2079 (2009).<pub-id pub-id-type="pmid">19505943</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez</surname><given-names>F</given-names></name><etal/></person-group><article-title>deepTools2: A next generation web server for deep-sequencing data analysis</article-title><source>Nucleic Acids Res</source><year>2016</year><volume>44</volume><fpage>W160</fpage><lpage>W165</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw257</pub-id><pub-id pub-id-type="pmid">27079975</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Ramirez, F. et al. deepTools2: A next generation web server for deep-sequencing data analysis. <italic>Nucleic Acids Res</italic><bold>44</bold>, W160&#x02013;W165 (2016).<pub-id pub-id-type="pmid">27079975</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Orkin</surname><given-names>SH</given-names></name><name><surname>Yuan</surname><given-names>GC</given-names></name></person-group><article-title>CUT&#x00026;RUNTools: A flexible pipeline for CUT&#x00026;RUN processing and footprint analysis</article-title><source>Genome Biol.</source><year>2019</year><volume>20</volume><fpage>192</fpage><pub-id pub-id-type="doi">10.1186/s13059-019-1802-4</pub-id><pub-id pub-id-type="pmid">31500663</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Zhu, Q., Liu, N., Orkin, S. H. &#x00026; Yuan, G. C. CUT&#x00026;RUNTools: A flexible pipeline for CUT&#x00026;RUN processing and footprint analysis. <italic>Genome Biol.</italic><bold>20</bold>, 192 (2019).<pub-id pub-id-type="pmid">31500663</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Model-based analysis of ChIP-Seq (MACS)</article-title><source>Genome Biol.</source><year>2008</year><volume>9</volume><fpage>R137</fpage><pub-id pub-id-type="doi">10.1186/gb-2008-9-9-r137</pub-id><pub-id pub-id-type="pmid">18798982</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). <italic>Genome Biol.</italic><bold>9</bold>, R137 (2008).<pub-id pub-id-type="pmid">18798982</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Neph</surname><given-names>S</given-names></name><etal/></person-group><article-title>BEDOPS: High-performance genomic feature operations</article-title><source>Bioinformatics</source><year>2012</year><volume>28</volume><fpage>1919</fpage><lpage>1920</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts277</pub-id><pub-id pub-id-type="pmid">22576172</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Neph, S. et al. BEDOPS: High-performance genomic feature operations. <italic>Bioinformatics</italic><bold>28</bold>, 1919&#x02013;1920 (2012).<pub-id pub-id-type="pmid">22576172</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>LG</given-names></name><name><surname>He</surname><given-names>QY</given-names></name></person-group><article-title>ChIPseeker: An R/Bioconductor package for ChIP peak annotation, comparison and visualization</article-title><source>Bioinformatics</source><year>2015</year><volume>31</volume><fpage>2382</fpage><lpage>2383</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btv145</pub-id><pub-id pub-id-type="pmid">25765347</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Yu, G., Wang, L. G. &#x00026; He, Q. Y. ChIPseeker: An R/Bioconductor package for ChIP peak annotation, comparison and visualization. <italic>Bioinformatics</italic><bold>31</bold>, 2382&#x02013;2383 (2015).<pub-id pub-id-type="pmid">25765347</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Lun</surname><given-names>AT</given-names></name><name><surname>Perry</surname><given-names>M</given-names></name><name><surname>Ing-Simmons</surname><given-names>E</given-names></name></person-group><article-title>Infrastructure for genomic interactions: Bioconductor classes for Hi-C, ChIA-PET and related experiments</article-title><source>F1000Res</source><year>2016</year><volume>5</volume><fpage>950</fpage><pub-id pub-id-type="doi">10.12688/f1000research.8759.1</pub-id><pub-id pub-id-type="pmid">27303634</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Lun, A. T., Perry, M. &#x00026; Ing-Simmons, E. Infrastructure for genomic interactions: Bioconductor classes for Hi-C, ChIA-PET and related experiments. <italic>F1000Res</italic><bold>5</bold>, 950 (2016).<pub-id pub-id-type="pmid">27303634</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Kent</surname><given-names>WJ</given-names></name><name><surname>Zweig</surname><given-names>AS</given-names></name><name><surname>Barber</surname><given-names>G</given-names></name><name><surname>Hinrichs</surname><given-names>AS</given-names></name><name><surname>Karolchik</surname><given-names>D</given-names></name></person-group><article-title>BigWig and BigBed: Enabling browsing of large distributed datasets</article-title><source>Bioinformatics</source><year>2010</year><volume>26</volume><fpage>2204</fpage><lpage>2207</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq351</pub-id><pub-id pub-id-type="pmid">20639541</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Kent, W. J., Zweig, A. S., Barber, G., Hinrichs, A. S. &#x00026; Karolchik, D. BigWig and BigBed: Enabling browsing of large distributed datasets. <italic>Bioinformatics</italic><bold>26</bold>, 2204&#x02013;2207 (2010).<pub-id pub-id-type="pmid">20639541</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>